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ABBREVIATIONS 
2DE, 2D electrophoresis 
AEs, anion exchangers 
APCs, antigen-presenting cells 
ARF6, ADP-ribosylation factor 6 
ASCs, adipose tissue-derived stem cells 
ATP, adenosine triphosphate 
BCA, bicinchoninic acid 
b-FGF, basic fibroblasts growth factor 
BTs, bicarbonate transporters 
CAFs, cancer-associated fibroblasts 
CAs, carbonic anhydrases 
CCL, CC chemokine ligand 
CFDA-SE, Carboxyfluorescein diacetate succinimidyl ester 
CFPs, circulating population of fibroblasts precursors 
CPM, counts per minute 
CSCs, cancer stem cells 
CXCL, chemokine (C-X-C motif) ligand 
DCs, dendritic cells  
DMEM or DME, Dulbecco's Modified Eagle's Medium 
DTT, dithiothreitol 
ECM, extracellular matrix 
ECs, endothelial cells 
ED-A, extra-domain A 
EGF, epidermal growth factor 
EMM-PRIN, extracellular matrix metalloproteinases inducer 
EMT, epithelial-mesenchymal transition 
EMVs, extracellular membrane vesicles 
EndMT, endothelial-mesenchymal transition 
ERK, extracellular signal regulated kinase 
ESCRT, endosomal sorting complex required for transport 
FAP, fibroblasts activation protein 
FBS, fetal bovine serum 
FGF, fibroblasts growth factor 
FSP1, fibroblasts specific protein 1 
GAPDH, glyceraldehyde-3-phosphate dehydrogenase 
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GLUT, glucose transporters 
HDFs, human dermic fibroblasts 
HGF, hepatocyte growth factor 
HIF-1, hypoxia-inducible factor 1 
HPFs, human prostatic fibroblasts 
HSCs, hematopoietic stem cells 
ICAM, intercellular cell adhesion molecule 
IFN, interferon 
IGF, insulin growth factor 
IL, interleukin  
ILVs, intraluminal vesicles 
IMG, intussusceptive microvascular growth 
LFA-1, lymphocyte function-associated antigen 1 
LOX, lysyl oxidase 
LPS, lipopolysaccharide 
MCP-1, monocyte chemoattractant protein 1 
MCTs, monocarboxylate transporters 
MDCs, myeloid dendritic cells 
MDSCs, myeloid-derived suppressor cells 
MFs, myofibroblasts 
MHC, major histocompatibility complex 
MLCK, myosin light-chain kinase 
MMPs, matrix metalloproteinases 
MMT, mesenchymal-mesenchymal transition 
MSCs, bone marrow-derived mesenchymal stem cells 
MVBs, multivesicular bodies 
MVs, microvesicles 
NBCs, Na+/HCO3- cotransporters 
NDCBE, electroneutral Na+-driven Cl-/HCO3- exchanger 
NHE, Na+/H+ exchanger 
NK, natural killer 
NSF, N-ethylmaleimide-sensitive factor 
PARs, protease-activated receptors 
PBS, phosphate-buffered saline 
PC3-GFP, green fluorescent protein (GFP)-expressing PC3 cells 
PCP, planar cell polarity 
PDCs, plasmacytoid dendritic cells 
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PDGF, platelet-derived growth factor 
PG, proteoglycan 
pHe, extracellular pH 
pHi, intracellular pH 
PI3K, phosphatidylinositol 3-kinase 
PKM1, pyruvate kinase M1 isoform 
PKM2, pyruvate kinase M2 isoform 
PLD, phospholipase D 
pO2, oxygen pressure 
PVDF, polyvinylidene difluoride 
ROS, reactive oxygen species 
SDF-1, stromal cells-derived factor 1 
SNAP, soluble NSF-attachment protein 
SOD-2, superoxide dismutase 2 (mitochondrial isoform) 
SP, signal peptide 
SSC, squamous cell carcinoma 
TAMs, tumor-associated macrophages 
TF, tissue factor 
TGF-β, transforming growth factor-β 
TNF, tumor necrosis factor 
Treg, regulatory T cells 
uPA, urokinase-type plasminogen activator 
V, relative spot volume 
V-ATPase, vacuolar proton pump ATPase 
VEGF, vascular endothelial growth factor 
α-SMA, α-smooth muscle actin 
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INTRODUCTION 
TUMOR INITIATION AND PROGRESSION 
Tumors are genetic diseases that arise through a multi-step process in which the 
accumulation of mutations occurs mainly in genes involved in cell proliferation and 
differentiation or in cell death. To date, there are two different theories whose aim is 
to explain how a cell can collect the number of genetic changes needed to convert 
its normal phenotype into malignant. 
The first hypothesis, initially move by Loeb et al. in 1974, originated from the 
observation that some tumors had multiple alterations compared to non-
transformed tissues both in the karyotype (aneuploidy, translocations or 
rearrangements of chromosomes) and in nucleotide composition (deletions, 
insertions and substitutions of single nucleotides), which, it was thought, can not 
be explained by the normal mutation frequency. Therefore, Loeb et al. proposed the 
mutator phenotype theory, according to which genetic alterations in cancer cells 
occur more frequently than in normal ones [1, 2]. The difference in mutation rate 
was associated with cancer genetic instability due to alterations in genes encoding 
proteins responsible for the control of DNA replication and/or repair, as well as 
involved in chromosome segregation, in checkpoints surveillance during cell cycle, 
in cellular balance between death and birth, and in maintenance of CpG-island 
methylation patterns [2, 3]. In this hypothesis, genetic instability is responsible for 
the genotypic heterogeneity, characteristic of the tumor mass and represents the 
driving force of carcinogenesis [4]. 
The theory of the mutator phenotype in cancer was first re-examine by Nowell in 
1976, who added the concept of clonal evolution to that of genetic instability [5], 
and then argued by Bodmer and Tomlinson in mid-nineties, which suggest that 
natural selection has a more important role with respect to genetic instability in 
tumor initiation and progression. This hypothesis derives from the observation that 
chromosomal or nucleotide instability is not a common feature of all cancers and is 
not a conditio sine qua non in tumorigenesis [6, 7]. On the contrary, it is widely 
accepted that tumor growth is a form of evolutionary process: through the 
mechanism of natural selection, only the cell carrier of one or more advantageous 
mutations is able to evade anti-growth signals and the result is an uncontrolled 
proliferation; after that other random genetic changes occur, each followed by waves 
of selection and expansion of most suitable clones. This process, together with the 
high rate of cell turnover, could explain the multiple alterations characteristic of 
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some cancers. The expression in the malignant cells of a mutator phenotype can, 
however, promote tumor progression, making it faster [6, 7]. To date, it is not clear 
whether the genetic instability is cause or consequence of tumorigenesis. In 
contrast, the hypothesis of natural selection and clonal evolution is validated and it 
is thought that this process has an important role in establishing the behavioral 
and morphological heterogeneity of cancer cells [8, 9]. 
In the last 30-40 years, many studies have suggested that the high heterogeneity of 
tumor mass can also reflect the hierarchical organization of stem/progenitor cells 
system, without necessarily excluding the stochastic model of clonal evolution [10]. 
In cancer of hematopoietic system, brain, breast and prostate have been identified 
biologically distinct populations of “tumor initiating cells”, which have a similar 
behavior to stem cells of normal tissue, and for this reason are also known as 
cancer stem cells (CSCs) [11-15]. 
The properties that characterize normal stem cells are an extended, often unlimited 
proliferative potential, the high telomerase activity and the self-renewal ability 
through both a symmetric cell division (i.e. both daughter cells maintain the 
properties of progenitor) and asymmetric one (i.e. a daughter cell retains stem cells 
properties, while the other one begins the differentiation process which leads to the 
formation of a progeny capable of expressing different functional mature 
phenotypes). According to these abilities, the role of the CSCs can be identified in 
three interconnected contexts: by symmetric and/or asymmetric division they 
produce the heterogeneous population of malignant cells within a primary tumor, 
form the drug-resistant stem cells niche responsible for relapses following 
chemotherapy-induced remission and generate metastasis. It was hypothesized that 
CSCs arise from genetic changes in normal stem cells, or from progenitors, that, for 
definition, are provided with a significant replicative capacity, but regain self-
renewal property after mutations [16-19]. 
Therapeutic strategies specifically directed to CSCs are considered the only ones 
able to eradicate the disease by reducing the risk for relapse and metastasis [10]. 
Figure I shows an overview of cancer development, where none of the theories 
mentioned above is excluded. 
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The hallmarks of cancer cells 
Cancers expand as clones from individual transformed cells and are diseases in 
continuous evolution due to the process of tumor progression, which generates 
subpopulations with increasing aggressiveness [20]. Tumor progression, in fact, 
consists in the progressive loss of differentiation due to morphological and 
metabolic alterations of tumor cells and is the result of several mechanisms (such 
as changes in gene expression, inactivation of tumor suppressor genes or activation 
of oncogenes) caused by chromosomal abnormalities, point mutations and an 
aberrant status of DNA methylation [20-22]. 
The accumulation of multiple alterations leads transformed cells to acquire 
characteristics and properties typical of malignancy by providing a competitive 
advantage compared with their normal counterpart. The new functional capabilities 
showed by most (if not all) cancer cells include: growth factor-independent 
proliferation, evasion of anti-growth signals, resistance to apoptosis, unlimited 
 
Figure I. Outline of cancer development. Tumor evolves by a reiterative process of genetic 
diversification and clonal selection, in fact only the cells with advantageous alterations (driver mutations) 
undergo clonal expansions, thus producing a tumor mass and causing the phenotypic heterogeneity 
typical of its cells. In this context, genome instability can promote tumor development. During this 
multistep process, cancer cells acquire distinct biological capabilities (or hallmarks), thereby increasing 
their aggressiveness and malignancy. Cells with the stemness properties have a relevant role in the 
development and perpetuation of various tumors. 
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proliferative potential, induction of neoangiogenesis, tissue invasion and metastasis 
[23-24] (Figure I). 
In normal tissue, cell proliferation is a controlled event, strictly balanced through 
anti-proliferative signals, or induction of programmed cell death in order to ensure 
the cell number required to maintain the correct tissue architecture and thus its 
function. Cell proliferation is promoted by an exogenous paracrine signal (growth 
factor), that binds and activates a specific cell surface receptor (mainly with 
intrinsic tyrosine kinase activity), which, in turn, triggers the intracellular signaling 
pathway. In contrast, anti-proliferative signals block cell growth by leading somatic 
cells to a quiescent state, thereby ensuring a homeostasis of cell number, or in a 
state of post-mitotic irreversible arrest corresponding to the acquisition of a 
functional phenotype [23]. The activation of apoptotic machinery, instead, occurs in 
detrimental or stress conditions, such as DNA damage, hypoxia, or survival factors 
shortage, thus preventing tumor initiation [25]. A further proliferative barrier typical 
of normal cells is the senescence [26], a process related to telomeres shortening due 
to the inability of DNA polymerase to replicate these chromosomal regions during S 
phase of the cell cycle and because of lack of telomerase gene expression, a 
specialized DNA polymerase able to perform this action. In fact, normal cells can 
replicate only a limited number of times and, when exhaust the telomeric region, 
enter into a non proliferative but viable condition until reaching crisis state and 
subsequent death by apoptosis [24]. 
Unlike their normal counterpart, tumor cells proliferation is mainly autonomous 
and decoupled from external mitogenic signals (Figure I). This independence can be 
acquired through multiple ways: tumor cells become able to synthesize growth 
factors for which express specific receptors (autocrine stimulation) [27], overexpress 
a particular receptor becoming more responsive to the normal concentration of 
ligand [27], express constitutively activated surface receptors [27] or integrins 
(receptors that mediate cell-matrix and cell-cell contact) that promote cell survival 
and growth [28, 29], and have an aberrant regulation of Sos-Ras-Raf-MAPK cascade 
which continues to transmit an intracellular mitogenic signaling also in absence of 
normal upstream stimulatory signals [30]. The result is that tumor mass size 
increase depends on growing number of malignant cells that divides in a unit of 
time. They, in fact, besides acquiring the ability to sustain chronic proliferation, are 
capable to circumvent antigrowth signals (Figure I), principally deregulating the two 
canonical suppressor of proliferation: RB protein (retinoblastoma-associated), which 
controls the entry into cell cycle especially depending on extracellular signals [31-
33] and p53, which arrest the cell in G1/S phase of the cell cycle if DNA is damaged, 
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if nucleotide pool are depleted, or if nutrient are suboptimal, and elicit apoptotic 
program when stress condition continues [24]. The mutations that impair p53 
function [34, 35] together with the increased expression of apoptosis inhibitors (Bcl-
2, Bcl-xL), the down-regulation of pro-apoptotic factors (Bax, Bim and Puma) and 
the activation of phosphatidylinositol 3-kinase (PI3K)-Akt survival pathway belong 
also to the strategies that enable cancer cells to escape programmed cell death [24, 
25]. 
In addition to uncontrolled growth and resistance to apoptosis, tumor cells show an 
unlimited replicative potential mainly (in 85-90% of cases) thanks to telomerase 
gene up-regulation [36] or in a smaller number of cases by a recombination-
mediated mechanism, termed ALT (alternative lengthening of telomeres) [37] (Figure 
I). The acquisition of these biological traits makes tumor cells capable of giving rise 
to macroscopic tumors, sometimes visible to the naked eye. 
Similarly to what happens during embryogenesis, wound healing or female 
reproductive cycling, the formation of these cancer masses is accompanied by the 
growth of new blood vessels [38-40] (Figure I). In fact, like normal tissue, tumors 
require nutrients and oxygen supplies as well as the elimination of metabolic waste 
and carbon dioxide [24]. 
The formation of new blood vessels (termed angiogenesis) is turned on by a process 
called “angiogenic switch”, which surprisingly occurs during the early stages of 
neoplastic progression when the balance between pro- and anti-angiogenic factors 
shifts towards a pro-angiogenic outcome [39] (Figure II). Among the most common 
strategies used to move this balance there are the up-regulation of vascular 
endothelial growth factor-A (VEGF-A) [41-43] and/or fibroblasts growth factor (FGF) 
[44], which stimulate endothelial cells (quiescent in normal adult tissue) to 
continuously form new vessels, and the down-regulation of trombospondin 1 (TSP-
1) [45] or β-interferon, whose role is to inhibit angiogenesis [46, 47]. The results are 
a vasculature convoluted and tortuous, and vessels enlarged, with an abnormal 
structure that cause disturbed blood flow [48, 49]. 
In addition to fulfill metabolic and proliferative needs of tumor cells, the new vessels 
represent one of the means by which such cells escape from primary tumor and 
colonize other parts of the body giving rise to metastasis (Figure I). This multistep 
process begins with the detachment of transformed cells from the extracellular 
matrix at the site of the primary tumor, follows with the intravasation into nearby 
vessels, the dissemination into the bloodstream, both directly from the venous 
capillary and indirectly via lymphatic system, and with the passage through blood 
vessels wall into the parenchyma of the secondary site where metastasis will grow 
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[50, 51]. Invasion and metastasis are the typical characteristics of malignancy, in 
fact, colonization by tumor cells of distant tissues is the cause of 90% of human 
cancer deaths [52]. These properties are obtained by tumor cells thanks to the loss 
of expression or mutations of E-cadherin gene, a key factor of cell adhesion [53-55], 
or of gene encoding other mediators of cell-cell or cell-matrix contact and/or the up-
regulation of genes encoding proteins involved in cell migration, such as N-cadherin 
[55]. During invasion and metastasis processes, epithelial transformed cells activate 
the epithelial-mesenchymal transition (EMT) program, which leads to assume a 
mesenchymal phenotype characterized by increased migratory capacity, by high 
resistance to apoptosis, by an elongated, spindle-shaped morphology, by the 
expression of matrix-degrading enzymes [56-60] and by the acquisition of stem cell-
like capability of self-renewal [61]. Invasion and metastasis are complex processes 
completed only by transformed cells that present every hallmark described above 
[23]. 
THE TUMOR MICROENVIRONMENT 
Solid tumors are complex tissues composed not only of highly heterogeneous cancer 
cells but also of abundance cellular and non-cellular components, also known as 
tumor microenvironment, that play an important role in cancer initiation, growth 
and progression (Figure II). The cellular elements include both cells normally 
present in the parenchyma tissue or migrated as a result of tumorigenesis, such as 
fibroblasts, endothelial cells and pericytes, and a plethora of immune/inflammatory 
cells mostly recruited from circulation or bone marrow, in particular T- and B-cells, 
macrophages, neutrophils, mast cells and other bone marrow-derived cells [62] 
(Figure II). These two groups of cells are responsible for the synthesis of the variety 
of molecules representing the non-cellular components of tumor-associated stroma, 
such as the extracellular matrix (ECM) proteins, proteases, cytokines and growth 
factors. 
Other elements capable to affect the behavior of malignant cells are extracellular 
pH, oxygen (O2) concentration, tissue pressure and fluid flow, also these physical 
and chemical parameters belong to the non-cellular components of tumor 
microenvironment [63] (Figure II). The structure and the composition of TM are 
highly variable, with differences seen among various types of cancer, often in 
different areas of the same tumor and between patients [64]. Cancer cells can 
remodel the traits of microenvironment during disease progression, in turn, tumor-
associated stroma not only functions as a supporting “scaffold” but also actively 
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participates to tumorigenesis contributing to the development and expression of 
certain hallmark capabilities [24, 65-67]. 
Fibroblasts 
Activated fibroblasts 
Fibroblasts are the most abundant cellular elements in connective tissue and with 
the fibrillar ECM, within they are embedded, form the structural scaffolding of 
organs. These cells are morphologically well described, they have an elongated 
shape and a typical fusiform or spindle-like profile; but not molecularly 
characterized, so are identified for what they are not: vascular, epithelial and 
inflammatory cells [69] (Figure III). 
Fibroblasts have multiple roles: they synthesize many of the constituents both of 
fibrillar ECM (such as type I, type III and type V collagen, and fibronectin) [70, 71] 
and of basal lamina (for example type IV collagen and laminin) [72]; are responsible 
for the remodeling and turnover of ECM by secreting matrix metalloproteinases 
(MMPs) [72, 73]; regulate differentiation and homeostasis of adjacent epithelia 
 
Figure II. The tumor microenvironment. Tumor cells acquire the capabilities to resist cell death and to 
avoid immune destruction, but tumor growth is also promote by the other cellular components of tumor 
microenvironment. TAMs support growth, angiogenesis and invasion, by secreting numerous pro-
tumorigenic proteases, cytokines and growth factors (such as EGF). MDSCs and Treg cells, mobilized into 
the circulation by various cytokines (as TGF-β, and CXCL5-CXCR2), disrupt immune surveillance. CAFs, 
activated by tumor-derived factors (as TGF-β, FGF or PDGF), secrete ECM proteins and basement 
membrane components, modulate immune responses, support angiogenesis. Other extracellular elements 
contribute to tumor progression, including low O2 tension, high interstitial fluid pressure and change in 
specific constituents of the ECM. EndMT, endothelial-mesenchymal transition; Ag, antigen; TAMs, tumor-
associated macrophages; CAFs, cancer-associated fibroblasts; MDSCs, myeloid-derived suppressor cells; 
Treg, regulatory T cells; EGF, epidermal growth factor; TGF-β, transforming growth factor; PDGF, platelet-
derived growth factor [68]. 
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through the secretion of growth factor or other soluble molecules involved in 
mesenchymal-epithelial interactions [74]; are important participants in 
inflammatory response to tissue damage and in wound repair [70, 75]. 
When tissue injury occurs, healing fibroblasts invade the wound and proliferate 
faster than normal ones both in order to replace lost or damaged fibroblasts due the 
injury, and to increase its number facilitating tissue repair [76]. Moreover, 
fibroblasts secrete increased amounts of ECM constituents and MMPs, and 
generate larger contraction forces promoting wound closure [77]. Healing 
fibroblasts, also known as myofibroblasts (MFs), are characterized by an “activated” 
phenotype [78, 79]. They acquire contractile stress fibers, de novo express α-smooth 
muscle actin (α-SMA) and the alternatively spliced fibronectin isoform containing 
the extra-domain A (ED-A), and are connected to each other by gap junctions [70] 
(Figure III). To support the intense production of ECM components, activated 
fibroblasts possess a dispersed chromatin form (euchromatin) with one or two 
nucleoli in the nucleus, rough endoplasmic reticulum and a well developed Golgi 
apparatus [69]. 
Fibroblasts activation is induced by various stimuli derived from injured epithelia 
cells, which secrete transforming growth factor-β (TGF-β), epidermal growth factor 
(EGF) and basic-fibroblasts growth factor (b-FGF), otherwise they can be activated 
by direct cell-cell contact and communication with leukocytes [80, 81]. 
 
Figure III. Fibroblasts activation. Normal fibroblasts are embedded within the fibrillar ECM of the 
connective tissue, have a fusiform shape, a prominent actin cytoskeleton and vimentin intermediate 
filaments. Activated fibroblasts (or MFs) differ morphologically and functionally from the quiescent ones. 
In response to mechanical tension, activated fibroblasts acquire stress fibers, express α-SMA and ED-A 
splice variant of fibronectin, in addition, form cell-cell contacts through gap junctions. Considering that 
“tumors are wound that do not heal”, CAFs share several similarities with MFs. Once activated, CAFs 
produce proteases, growth factors, cytokines and enzymes. FN, fibronectin; FSP1, fibroblasts specific 
protein 1; FAP, fibroblasts activation protein [modified from ref. 149]. 
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The transition from quiescent fibroblasts to activated ones is reversible, in fact, 
when the stimulus is turned off the number of MFs decreases and the site, now 
healed, is repopulated of resting fibroblasts with a normal phenotype [69, 77] 
(Figure III). 
Fibroblasts not only are the main cellular element of normal stroma, but also 
represent the most prominent cell type within reactive stroma of many solid tumors, 
as breast, prostate and pancreatic carcinoma [82, 83] (Figure II). Peritumoral 
fibroblasts, also known as cancer-associated fibroblasts (CAFs) [84, 85], have a 
phenotype similar to healing fibroblasts (including the expression of α-SMA and of 
ED-A fibronectin), but, unlike them, persist in the activated state. For this reason, 
tumors are considered as “wounds that do not heal” [86] (Figure III). 
Cancer-associated fibroblasts 
Heterogeneous subpopulations of fibroblasts has been observed in the margins and 
infiltrated in tumor mass. They are not always easy identified, because express 
several markers in common with other stromal cellular elements [82] and only 
partially share the expression of known markers of the activated state, as α-SMA, 
fibroblasts specific protein 1 (FSP1), platelet-derived growth factor (PDGF) receptor 
β and fibroblasts activation protein (FAP) [87, 88]. This heterogeneity may in part 
reflect the multiple origins of CAFs. At a glance, the predicted sources of CAFs are 
fibroblasts resident in the tumor site [89] (Figure IV). In fact, within tumor 
microenvironment, cancer cells secrete numerous growth factors (TGF-β, PDGF and 
b-FGF), cytokines and chemokines that, through specific receptors present on local 
fibroblasts surface, trigger various tumor-promoting pathways. As result of this 
process, commonly called mesenchymal-mesenchymal transition (MMT), fibroblasts 
increase the production of ECM components, pro-angiogenic factors, chemokines 
and interleukins [90, 91]. 
Alternative sources of CAFs are bone marrow-derived mesenchymal stem cells 
(MSCs), hematopoietic stem cells (HSCs), and adipose tissue-derived stem cells 
(ASCs) (Figure IV). MSCs are able to differentiate into mesenchymal tissue cells as 
bone, fat, cartilage, muscle and fibroblasts [92, 93], in fact, they are recruited to 
damaged sites during tissue repair, inflammation and to the tumor stroma in 
different cancer types, as breast, pancreatic and ovarian adenocarcinoma [94-98]. 
MSCs, recruited to the tumor site, thanks to growth factor (as VEGF, EGF, 
hepatocyte growth factor or HGF, b-FGF and PDGF) and cytokines (as monocyte 
chemoattractant protein 1, MCP-1, also known as CC chemokine ligand 2, CCL2) 
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secreted by cancer cells or by reactive stroma, differentiate into pericytes, MFs and 
endothelial cells contributing to the CAF populations [99-102]. 
HSCs, instead, are able to give rise to all functional blood cells and are precursors 
of osteoclasts and mast cells. Recent studies showed that a circulating population 
of fibroblasts precursors (CFPs) derived from HSCs are present in tumor mass. 
Their recruitment is mainly mediated by MCP-1 and by stromal cells-derived factor 
1 (SDF-1), also known as chemokine (C-X-C motif) ligand 12 (CXCL12) [103]. The 
transition of HSCs-derived CFPs to the activated phenotype is mediated by TGF-β 
[104-106]. 
The signaling pathway triggers by TGF-β has an important role also in the 
activation of ASCs, which are able to give rise to CAF-like cells when treated with 
conditioned media from breast cancer cell lines [107]. 
Another proposed sources of CAFs are cells of epithelial origin and endothelial cells, 
which, respectively through EMT [82, 108] and endothelial-mesenchymal transition 
(EndMT) [109], acquire fibroblasts morphology and express high levels of α-SMA 
[109, 110] (Figure IV). Similarly, CAFs can stem directly from carcinoma cells 
through EMT, which enhances their migration and invasion ability [82, 108, 111] 
(Figure IV). Finally, pericytes, i.e. cells present within the basement membrane of 
Pericytes
Bone 
Marrow
HSCs
MSCs
Tumor Cells
Adipocytes
Resident
Fibroblasts
Endothelial CellsEpithelial Cells
CAFs
 
Figure IV. Multiple origins of CAFs within tumor microenvironment. CAFs can derive from resident 
fibroblasts through MMT, from MSCs, HSCs, ASCs, and pericytes. Alternatively, CAFs can stem from 
epithelial and cancer cells through EMT, or from endothelial cells through EndMT [modified from ref. 115-
116]. 
Introduction 
14 
 
capillaries and post-capillary venules often located closer to the tumor site, are 
another plausible source of CAFs [112, 113] (Figure IV). 
The precursors of CAFs pool of reactive stroma can vary with tumor type, during its 
progression and in the different areas of the same tumor. Considering the multiple 
origins suggested and the difficulty of identifying specific markers, Madar et al. had 
recently proposed a new definition for CAFs, as a cell “state” rather than a cell type. 
In other words, cells of different origins can exhibit CAFs state, which is a dynamic 
condition of fibroblasts-like cells acquired in the vicinity of tumor 
microenvironment, that actively promote cancer progression [114]. 
The role of CAFs in cancer initiation and progression 
The activation of fibroblasts is mediated by numerous growth factors and cytokines 
secreted by cancer cells, such as TGF-β [117], PDGF-α/β [118, 119], b-FGF [120] 
and interleukin (IL) -6 [121] (Figure V). In turns, altered fibroblasts are able to 
promote tumor initiation, its progression and metastasis. 
The direct involvement of fibroblasts in cancer initiation was demonstrated by using 
mouse as xenograft model organism. In this context, Olumi et al. showed that 
immortalized epithelial cells, co-injected into mice with CAFs obtained from the 
primary tumor site, form cancerous masses, on the contrary, this effect does not 
occur in presence of normal fibroblasts [122]. Indeed, CAFs express high levels of 
epithelial mitogens, as HGF, EGF, b-FGF and cytokines, as SDF-1 and IL-6, which 
alone are sufficient to induce the transformation of adjacent epithelial cells and 
thus to favor tumor formation [123]. Modified fibroblasts can directly stimulate the 
proliferation of cancer cells by providing growth factors, or indirectly by helping 
these cells to evade apoptosis. They, in fact, secrete survival factors, as insulin 
growth factor (IGF)-1 and -2 [124, 125], and produce many ECM constituents 
(mainly various types of collagen), thereby promoting the ligation between integrin 
receptors and collagen fibers [126]. Both actions promote tumor cells survival via 
activation of the PI3K/Akt signaling pathway (Figure V). 
In addition to providing part of the ability of cancer cells to resist apoptosis, the 
CAFs-mediated ECM remodeling can also promote tumor invasion and metastasis. 
Activated fibroblasts, in fact, are able to cause qualitative and quantitative changes 
in ECM, which becomes stiffer [127, 128]. Part of this process can be attributed to 
an increased number of covalent cross-links between collagen fibers and other ECM 
components due to an excess activities of lysyl oxidase (LOX), which is expressed by 
fibroblasts in the early stage and also in carcinoma cells in the later one [126, 129]. 
Increase in mechanical force as a result of LOX activity facilitates metastatic 
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process [126] (Figure V). Moreover, ECM anomalies, including rigidity, contribute, 
together with an altered vasculature, to increase interstitial fluid pressure 
supporting tumor drug resistance [130] (Figure V). 
CAFs are also a source of ECM-degrading enzymes, as MMPs and plasminogen 
activator (Figure V). In particular, stromal cells from colon and breast carcinoma 
express the urokinase-type plasminogen activator (uPA) system, composed of uPA 
and uPA receptor (uPAR), which induces the turnover of ECM through the 
activation of plasminogen to the serine protease plasmin [131]. These proteases, 
through the degradation of ECM, create a physical path enabling tumor cells to 
penetrate basement membranes, by facilitating the invasion of surrounding tissue. 
Other functions of MMPs and plasmin include the ability to cleave and thus to 
activate latent growth factors, pro-inflammatory cytokines and their receptors, to 
release ECM-bound growth factors, or to cleave cell adhesion molecules, 
contributing to increase cancer cells proliferation, their motility, EMT and 
angiogenesis [132, 133]. These actions have been elucidated for MMP-1, MMP-3 
(also known as stromelysin 1), MMP-13 and plasmin. The target of MMP-1 is the 
protease-activated receptor 1 (PAR1), a unique class of G protein-coupled receptors 
that, cleaved at the proper site, generate Ca2+-dependent signals promoting cancer 
cells migration and invasion [134]. MMP-3 directly cleaves E-cadherin ectodomain 
at the cell surface, leading normal mammary epithelial cells to lose cell-cell 
adhesion and to activate EMT program [135]. MMP-13 releases VEGF from ECM 
promoting tumor angiogenesis and thus the invasive phenotype [136]. Plasmin, 
instead, can activate some MMPs, such as MMP-3 and MMP-13 [137-139]. 
In addition, CAFs are able to affect cancer cells motility by secreting soluble 
mediators, as TGF-β, HGF, VEGF, FGF and SDF-1 [66, 140] (Figure V). Recently, 
Luga et al. showed a novel mechanism of communication between cancer and 
stromal cells. These last, in fact, are able to produce small membrane vesicles (in 
particular exosomes), which play a key role in promoting breast cancer cells 
protrusive activity and motility via Wnt-planar cell polarity (PCP) signaling [141] 
(Figure V). 
Further, there is evidence that stromal fibroblasts favor the dissemination of 
malignant cells through lymphatic and blood vessels, as well as are important in 
preparation of metastatic niche [142-144]. In keeping with this idea, cancer cells, 
endowed of self-renewal and tumor propagating capacity, function as “seeds”, 
instead the distant tissue together with fibroblasts derived from the primary tumor, 
represents the “soil” [145, 146]. In fact, CAFs co-traveling with metastatic tumor 
cells reach the secondary site, where participate in the formation of a 
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microenvironment permissive for the growth of metastatic colonies [147]. In this 
new location cancer cells induce the activation of resident normal fibroblasts [148]. 
Other important factors secreted by activated fibroblasts in tumor 
microenvironment are pro-inflammatory cytokines, as interleukins, interferon and 
member of the tumor necrosis factors (TNF) family [149] (Figure V). In particular, 
expression of chemo-attractant cytokines and chemokines by intratumoral 
fibroblasts plays a key role in the recruitment of immune cells that, in turns, 
promote angiogenesis and metastasis [150]. Recent study showed that fibroblasts 
express a pro-inflammatory gene signature, which is already activated at initial 
hyperplastic stage in multistep skin tumorigenesis [151]. Therefore, fibroblasts are 
“educated” by cancer cells to express genes encoding several cytokines, including 
SDF-1, CXCL14 and CCL7 (Figure V). The secretion of SDF-1 from CAFs enhances 
the mobilization of endothelial precursor cells from bone marrow and their 
recruitment into the tumor neovasculature [152]. Furthermore, SDF-1 increases the 
invasive capacity of pancreatic cancer cells and, together with CXCL8 produced by 
these malignant cells, promotes the complete angiogenic responses (i.e. 
proliferation, invasiveness and tube formation) of recruited endothelial cells [153]. 
CXCL14 expression in prostate cancer CAFs is up-regulated, too. This factor acts in 
autocrine fashion increasing both proliferation and migration rate of activated 
fibroblasts, which, in turns, promote tumor growth, angiogenesis and macrophage 
infiltration [154]. In a similar way, CCL7, up-regulated in fibroblasts associated to 
oral squamous cell carcinoma (SSC) by paracrine IL-1α secretion from these 
malignant cells, increases the invasiveness of oral SSC [155]. 
Another way used by altered fibroblasts to support tumor progression is by 
engaging a metabolic interplay with cancer cells. Stromal fibroblasts, in fact, are 
able to participate in the complex regulation of tumor metabolism, but there are 
opposite hypotheses about how this is done. In 2006, Koukourakis et al. proposed 
that cells within tumor microenvironment establish a harmonious metabolic 
collaboration, where CAFs express metabolic pathways complementary respect to 
cancer cells [156]. According to Warburg effect, tumor cells use glucose by aerobic 
glycolysis producing lactate [157-159], and to compensate the lower efficiency of 
adenosine triphosphate (ATP) production, due to incomplete glucose oxidation, 
increase the uptake of this sugar [160-162]. This behavior allows the diversion of 
glycolytic intermediates into various biosynthetic pathways in order to form 
macromolecules and organelles, and thus new cells [163, 164]. In this context, 
stromal cells buffer and recycle products of anaerobic metabolism of cancer cells 
sustaining their survival [156]. 
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In 2009, instead, Pavlides et al. proposed a different model, whereby tumor cells 
induce a metabolic shift toward an aerobic glycolysis in stromal fibroblasts. The 
energy metabolites produced from aerobic glycolysis, i.e. lactate and pyruvate, are 
used by cancer cells in the mitochondrial tricarbossilic acids (TCA) cycle for ATP 
production via oxidative phosphorylation. This new theory is also known as “reverse 
Warburg effect” [165]. 
However, to better understand the metabolic interplay between tumor and stromal 
cells will be needed further confirmations. 
Endothelial Cells 
Other determinant cellular elements of stromal compartments are tumor-associated 
endothelial cells (ECs). ECs have a flattened shape and form a sheet (the 
endothelium) lining all blood vessels, which acts as cellular interface between the 
circulating blood and the vessel wall. ECs have an important role in tumor 
angiogenesis, in fact, angiogenic growth factors secreted by tumor cells or cells of 
the reactive stroma can directly activate receptors present on ECs promoting 
endothelial sprouting, branching, differentiation and survival [166, 167]. The 
formation of new blood network can occur by two mechanisms: vasculogenesis and 
angiogenesis. In the vasculogenesis, endothelial progenitor cells, present in the 
 
Figure V. Interactions between cancer cells and fibroblasts within tumor microenvironment. 
Cancer cells produce growth factors, cytokines and other molecules, which induce and maintain the 
fibroblasts activated phenotype. Once activated, fibroblasts produce growth factors and cytokines that 
sustain tumor progression by promoting ECM remodelling, cell proliferation, angiogenesis and EMT. IL, 
interleukin; INF, interferon. 
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vessel wall or recruited from the bone marrow, contribute to the formation of tumor 
vessels [168, 169]. 
Angiogenesis, instead, comprises two different mechanisms: endothelial sprouting 
and intussusceptive microvascular growth (IMG). The sprouting process is based on 
endothelial cells migration, proliferation and the budding of new tubes or the 
formation of bridges between existing ones. IMG is a phenomenon of splitting 
angiogenesis, where the existing vessels lumen is divides by the formation and 
insertion of tissue folds and columns of interstitial tissue [170, 171]. Besides the 
participation in tumor neovasculature, ECs serve as interface between circulating 
blood cells, tumor cells and the ECM, thereby playing a central role in controlling 
leukocyte recruitment, tumor cells behavior and metastasis formation [172]. 
Pericytes 
Pericytes are contractile cells, related to vascular smooth muscle cells, which wrap 
around the endothelial cells, establishing with them a close physical contact in the 
outer surfaces of the finest branches of the vascular tree (the capillaries and 
sinusoids). Recent studies showed that pericytes are associated with the 
neovasculature of most, if not all, cancers. In this context, they can stabilize blood 
vessels, inhibit endothelial proliferation, maintain capillary diameter, regulate blood 
flow and provide endothelial survival signals via heterotypic contacts and soluble 
factors [173-175]. Their recruitment into tumor blood vessels is dependent on 
PDGF-B secreted by endothelial cells [176]. Other studies, instead, found that 
tumors with few pericytes density on their vasculature were associated with an 
increase in the number of metastases [173, 177]. For these reasons, the role of 
pericytes in tumors is not completely understood and future research is needed. 
Immune/inflammatory cells 
Tumor infiltrating cells of immune/inflammatory system include populations with a 
different phenotype and thus functionally heterogeneous, mainly macrophages, 
dendritic cells (DCs), myeloid-derived suppressor cells (MDSCs) and neutrophils 
(Figure II). These cellular effectors can act in opposite ways both antagonizing or 
promoting tumor development, therefore the frequency of infiltrating inflammatory 
cells, their specific subset, as well as their maturation stage and spatial location 
within tumor microenvironment have determinant effects on clinical and 
immunologic outcomes [178, 179]. 
Macrophages are abundant components of tumor microenvironment, they originate 
from CD34+ bone marrow progenitors, which, in the circulation system, differentiate 
into monocytes and, once recruited in peripheral tissue, mature into macrophages 
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and exert specific immunological functions [180]. In tissues, monocytes can 
differentiate in two different phenotypes classified as M1 and M2 responses [181, 
182]. Their M1 polarization is mediated by inflammatory mediators, such as 
granulocyte macrophage-colony stimulating factor (GM-CSF), interferon-γ (IFN-γ) 
and lipopolysaccharide (LPS) [183]. Type 1 activated macrophages secrete pro-
inflammatory cytokines and chemokines, including CXCL19 and CXCL10 leading 
helper T lymphocytes 1 (Th1), Th17 and natural killer (NK) cells development and 
differentiation [184]. 
M2 profile, instead, is induced in response to macrophage-colony stimulating factor 
(M-CSF), IL-4, IL-10, IL-13, IL-21, CC chemokine receptor 4 (CCR4), or to 
immunosuppressive agents as Activin A, corticosteroids, prostaglandins (PGs) and 
vitamin D3 [181, 185]. M2 macrophages express a different set of cytokines and 
chemokines, such as CCL17, CCL22 and CCL24 promoting regulatory T cells 
recruitment and development [172]. According to their phenotypic characteristic, 
M1 macrophages have high microbicidal activity, immunostimulatory function and 
are present in incipient tumors, where are capable to kill tumor cells; on the 
contrary, M2 macrophages encourage tissue repair and remodeling, 
neoangiogenesis process and tumor invasion and metastasis [184]. Tumor cells can 
regulate the function of tumor-associated macrophages (TAMs), “educating” them 
toward an M2 phenotype [186-188] (Figure II). 
Dendritic cells, another type of bone marrow-derived mononuclear cells, are the 
preeminent antigen-presenting cells (APCs) for T lymphocytes in lymphoid organs 
and in tissue. In human, two distinct subpopulations of DCs have been identified, 
myeloid DCs (MDCs) and plasmacytoid DCs (PDCs) [189, 190]. Although their role 
is not yet clear, both types of DCs are implicated in tumor development but with 
different functions. MDCs inhibit tumor neoangiogenesis by producing IL-12 [191], 
on the contrary, PDCs, attracted in tumor microenvironment and protected by 
CXCL12 secreted by tumor cells, induce not only the formation of new vessels by 
producing TNF-α and IL-8 [192, 193] but also tumor progression and metastasis by 
secreting proteases, like MMP-1, -2, -3, -9 and -19 and their inhibitors, as tissue 
inhibitor metalloproteinases (TIMP) -1 and -2 [194]. 
In addition to these “mature” infiltrating cells, also MDSCs, an immature 
population of myeloid cells precursors of DCs, macrophages and/or granulocytes, 
are present in tumors [195, 196]. In this context, they are induced by various 
factors produced by malignant cells and/or cells of tumor microenvironment [197, 
198] and act as tumor-promoting cells by inhibiting innate and adaptive immunity, 
and by hindering immunotherapy [199]. 
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Also neutrophils are a component of the immune microenvironment of solid tumors 
[200-203]. These cells are recruited by CXCL8, a chemoattractant expressed by 
both cancer and stromal cells of many types of human tumors [201, 204]. 
Neutrophils are able to promote angiogenesis process by directly secreting VEGF, or 
inducing its release, or that of b-FGF from ECM, by producing MMPs [205, 206], 
but like other inflammatory cells also possess antitumor activity. In fact, they can 
kill tumor cells by releasing proteases, membrane perforating molecules, reactive 
oxygen species (ROS) and cytokines, in particular TNF-α and IL-1β [207]; otherwise, 
according the signals within tumor microenvironment, can inhibit angiogenesis by 
producing elastase [208, 209]. 
Hypoxia in the tumor microenvironment 
O2 is one of the most important elements required to sustain aerobic life. In aerobic 
organisms, as humans, cellular respiration encompasses a set of redox metabolic 
reactions based on the oxidation of glucose to carbon dioxide (CO2) and the 
reduction of O2 to water in order to generate the energy (ATP) necessary for 
biological processes. 
The air we breath contains about 21% O2 at atmospheric pressure of 760 mmHg, 
i.e. a value of 159 mmHg, but, already in the pulmonary alveoli, O2 pressure (pO2) 
comes down to about 2/3 to the one present in the ambient (66% of 159 ~ 100 
mmHg, that corresponds to a concentration of 14%). When the arterial blood 
reaches tissues peripheral capillaries, pO2 is still 100 mmHg, whereas that of 
interstitial fluids is 30 mmHg. This generates a pressure gradient which favors the 
movement of O2 from the blood into the adjacent tissue and thus its diffusion into 
the cellular mitochondria [210]. 
The intracellular pO2 necessary to satisfy normal metabolic requirements is 1-3 
mmHg. On the contrary, it is known, that in the context of cancer mass, among 
areas with normal O2 concentration, are present microregions with very low (down 
to zero) O2 partial pressures. In the tumor microenvironment, the impairment of O2 
delivery is related to the decrease of perfusion and diffusion. The first is associated 
to an inadequate blood flow caused by structural and functional abnormalities of 
tumor neovascularization. The latter is due to an increase of distance between 
vessels and cells present within cancer mass as a result of tumor expansion and 
often leads to cell death by necrosis [211, 212]. Studies concerning the oxygenated 
status of the tumor showed that: the median pO2 is lower in cancers compared to 
their normal counterparts; tumor microregions with low pO2 cannot be predicted by 
clinical size, stages, grade, histology and site; the oxygenation status of different 
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tumors is generally more variable than that of different areas of the same tumor; 
the oxygenation status of recurrent cancers is lower than that of the corresponding 
primary ones [213]. 
In solid tumors, the critical O2 partial pressure required to maintain the biological 
functions is between 45-50 mmHg in end-capillary blood and 0.02 mmHg in 
cytochromes. In fact, in the one hand, tumor cells reduced O2 consumption (i.e. 
respiration rates) when the pO2 in the blood at the venus end of the capillaries 
drops below 45-50 mmHg [214, 215] (Figure VI). On the other hand, cytochromes 
aa3 and c require O2 partial pressures greater than 0.02-0.07 mmHg to maintain 
respiration [216-218] (Figure VI). 
The hypoxic microenvironment is able to affects the behavior both of malignant and 
stromal cells (mainly fibroblasts and macrophages) and thus influences tumor 
propagation. In particular, hypoxia can induce a significant lengthening of G1 phase 
or the arrest into it, differentiation, programmed cell death and necrosis [219-226]. 
The induction of these phenotypes may explain delayed relapses, quiescent 
micrometastasis [227, 228] and growth retardation in large tumor masses [229]. 
 
Figure VI. Critical oxygen partial pressures that characterize the upper limit of the hypoxic range, below 
which activities or functions of tumor cells progressively change. Open bars: therapy form; hatched bars: 
cellular functions; solid bars: functions at the subcellular and molecular levels. The bars indicate the 
respective hypoxic ranges, with the lengths of the bevels showing the variation in threshold values as 
found by various authors for different end points [253]. 
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Into anoxic areas, instead, cells arrest their progression into cell cycle regardless of 
the phase in which they are. 
Besides to the impairment of neoplastic growth, hypoxia can promote tumor 
development by enabling the cells to adapt to low pO2 or to move from the original 
site to more suitable locations. Hypoxia induces the transcription of glycolytic 
enzymes (including hexokinase 2 and lactate dehydrogenase), glucose transporters 
(GLUT1 and GLUT3) (Figure VII), angiogenic molecules, survival and growth factors 
(such as VEGF, PDGF-β, angiogenin, Cyr61, TGF-β, IGF-2 and IL-8), enzymes, 
proteins able to promote tumor invasiveness (as uPA), chaperones and other 
resistance-related proteins [230-244], as well as the inhibition of integrin gene 
expression, thus supporting cell detachment [245]. The hypoxia-induced phenotype 
is the result of many variables, including the degree of hypoxia and 
microenvironmental epigenetic factors. For example, hypoxia-inducible factor 1 
(HIF-1), the master transcription factor induced in these stress conditions and the 
main responsible for the transcription of many genes encoding the proteins listed 
above, is able to exert opposite functions. Depending on the severity of hypoxia, 
HIF-1 can be in the dephosphorylated or phosphorylated status. The first form 
exerts pro-apoptotic effects, the other does not [246]. In addition, hypoxia can 
promote genomic instability (through point mutations and chromosomal 
aberrations) by increasing the number of genetic variants, and exerting a selective 
pressure can favor the expansion of the clone most suitable for this 
microenvironmental stress [232, 247-252] (Figure VI). Despite these observation is 
not yet clear the level of O2 at which hypoxia starts and causes biological problems. 
Acidosis in the tumor microenvironment 
The main effect due to tumor hypoxia is the decrease of mitochondrial functions 
(i.e. an impaired oxidative phosphorylation) and the shift to the glycolytic 
metabolism, which is a less energy-efficient process, but that does not rely on the 
presence of O2 [254, 255]. This “glycolytic switch” is often permanent and persist 
after reoxygenation because the metabolic intermediates (lactate and pyruvate) can 
be used for anabolic reactions leading to the biosynthesis of amino acids, 
nucleotides and lipids, thus providing a selective advantage to highly proliferative 
tumor cells [254, 255]. In addition, Sonveaux et al. showed that the lactate 
produced by tumor cells within hypoxic areas is used by malignant cells located in 
the vicinity of blood vessels as substrate for oxidative phosphorylation. As result of 
this symbiotic relationship, the limited glucose available in the tumor mass is used 
in an effective way [256]. In fact, the switch to glycolysis requires an increased 
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consumption of glucose and leads to an excessive generation of acidic catabolites, 
such as CO2, lactic acid, carbonic acid and protons (H+) (Figure VII). The release of 
these waste products in the extracellular space, together with the abnormal 
structure and function of tumor vasculature, is cause of the decline of extracellular 
pH (pHe), which usual is in the range of 6.5-7.0 [254, 257-260] (Figure VII). 
Besides hypoxia, also the acidity of the extracellular milieu is a stress condition, 
since lowering of the pHe makes more difficult the control of the intracellular one. 
In fact minimal variations in intracellular pH (pHi), as low as 0.1 pH units, may 
affect several biochemical and/or biological processes, as energy production, 
enzyme function, membrane integrity, metabolism, proliferation, migration, 
invasion and metastasis, drug resistance and apoptosis [255, 257, 261-264]. pH 
homeostasis in any cell type is a critical process that involves complex molecular 
mechanisms (i.e. a variety of proteins and buffer systems) [265], but this get tangled 
 
Figure VII. Proteins involved in pH regulation in cancer cells. The pHi-regulating system that 
participates in cytoplasmic alkalinization of tumor cells includes NHE1, the plasma membrane V-ATPase 
and MCTs, whose function is to actively export acid, and AEs, NBCs, which, instead, import HCO3-. Also 
carbonic anhydrases (CA II, CA IX and CA XII) contribute to cellular alkalinization by catalyzing the 
reversible hydration of CO2 to H+ and HCO3-. Hence, the pHi is slightly alkaline (pH 7.2-7.4), whereas the 
pHe is slightly acidic (pH 6.5-7.0). The glucose transporter GLUT1 (which is up-regulated in most tumors) 
imports glucose into cancer cells. The expression of the genes encoding most of these proteins is under 
the transcriptional control of HIF-1. CBP, cyclic AMP-responsive element-binding (CREB) protein; p300, 
histone acetyltransferase p300 [255]. 
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up for tumor cells, that prefer a more alkaline pHi (pH 7.4 o more) compared to 
their normal counterpart [256, 261, 265-268] (Figure VII). 
In cancer cells, the main players responsible for maintaining the alkaline pHi and 
the acidic pHe are: carbonic anhydrase (CA) II, CA IX and CA XII [269-271]; 
vacuolar proton pump ATPase (V-ATPase) [272]; the anion exchangers AE1 (also 
known as SLC4A1), AE2 ( also known as SLC4A2) and AE3 (also known as SLC4A3) 
[273, 274]; Na+/HCO3- cotransporters (NBCs) [275]; electroneutral Na+-driven Cl-
/HCO3- exchanger (NDCBE; also known as SLC4A8) [275]; Na+/H+ exchanger 1 
(NHE1; also known as SLC9A1) [275]; the monocarboxylate transporters MCT1, 
MCT2, MCT3 and MCT4 [276, 277] (Figure VII). The expression of these proteins 
enables cells to develop defense mechanisms providing a selective advantage, and 
thus fostering the survival even in an extracellular microenvironment with an 
increased acid load [278]. 
Carbonic Anhydrases 
The carbonic anhydrases (EC 4.2.1.1) are metalloenzymes whose major function is 
the catalysis of the reversible hydration of carbon dioxide to bicarbonate and 
protons (CO2 + H2O ↔ HCO3- + H+), a reaction of critical importance in most 
organisms since the bicarbonate/carbonic acid system is the main buffer in all 
living cells. They are presents in Archaea, prokaryotes and eukaryotes and are 
encoded by members of three independent gene families: α-CAs (present in 
vertebrates, eubacteria, algae and cytoplasm of green plants), β-CAs (mainly in 
eubacteria, algae and chloroplasts of both mono- as well as dicotyledons) and γ-CAs 
(found in Archaea and some eubacteria) [279-281]. 
CAs perform their enzymatic function mainly in presence of zinc, but a cadmium-
containing form was found to be expressed in marine diatoms during zinc limitation 
[282]. In mammals, 16 CA isoforms have been described (in human only 15 because 
CA XV in not present in primates). They differ in subcellular localization, tissue 
distribution, level of activity and susceptibility to different classes of inhibitors. 
There are cytosolic isoforms (CA I, CA II, CA III, CA VII and CA XIII), membrane 
bound ones (CA IV, CA IX, CA XII, CA XIV and CA XV), mitochondrial (CA VA and 
CA VB) and secreted isozymes (CA VI). In addition, there are three catalytic isoforms 
(CA VIII, CA X and CA XI), which are also known as CA-related proteins (CARP) 
[283, 284]. Among them all, CA IX and CA XII are overexpressed in many solid 
tumors, where they have an important role during the phase of progression, in 
metastases formation and in drug resistance [269-271, 285, 286]. 
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CA IX 
In 1992, Pastorekova and coworkers identified a cell density-regulated plasma 
membrane antigen in human HeLa cell line derived from cervical carcinoma using 
the monoclonal antibody M75 [287, 288]. Subsequently, cDNA sequence analysis of 
this antigen, named “MN protein”, showed a 257 amino acid residues long 
polypeptide highly homologous to the mammalian CA catalytic domain [271, 289]. 
Thus, being the ninth CA identified, the “MN protein”, was renamed CA IX [271, 
289]. 
CA IX protein is composed from a N-terminal extracellular domain linked through a 
hydrophobic transmembrane region with a C-terminal intracellular tail. The 
extracellular part, which represents the 90% of the whole protein is formed by a 
signal peptide (SP), a proteoglycan domain (PG) similar to the keratan sulfate-
binding domain of a large proteoglycan aggrecan, and by the CA catalytic domain 
[271, 289] (Figure VIII). 
Unlike other CA, isoform IX has a dimeric nature resulting from a intermolecular 
disulfide bond between two adjacent monomers and stabilized through two 
hydrogen bonds and numerous van der Waals interactions [290, 291]. Each 
monomer contains a compact globular catalytic domain, where the active site is 
located in a large conical cavity, that from the surface of the protein goes down to 
its center [269, 291]. In the bottom of this cavity is located the zinc (II) ion. 
Alongside of the active site is positioned the PG-like region, whose role is to ensure 
a better catalytic efficiency at more acidic pH values [292, 293]. In fact, pKa value 
measured for CA IX catalytic domain alone is 7.01, on the contrary, whenever the 
protein construct contains also the PG region the optimal catalytic activity is at pH 
6.49 [291]. PG domain function is probably mediated by its negatively charged 
amino acids. This region, by interacting with positively charged residues close to the 
active site, can both act as a cap controlling substrate accession and participate in 
the proton-transfer reaction [291]. 
CA IX
SP PG CA TM  IC
42 - 130 167 - 405
 
Figure VIII. Domains organization of the CA IX protein. SP: signal peptide, PG: proteoglycan-like 
domain, CA: catalytic domain, TM: transmembrane segment, IC: intracellular, cytosolic tail [292]. 
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Also the cytoplasmic tail can modulate CA IX catalytic activity both through the 
transmission of inside-out signaling to extracellular enzyme domain [294, 295] and 
increasing its activation [296, 297]. Similar to some cytosolic (CA I and CA II) and 
all extracellular CA isoforms, CA IX belongs to the highly active human α-CAs, as 
well as is susceptible to inhibition by anions and sulfonamides/sulfamates [269, 
290, 298, 299]. 
In normal tissue, CA IX is mainly expressed on the basolateral surface of 
proliferating crypt enterocytes of the duodenum, jejunum and ileal mucosa [300], 
while a weak expression is present in the epithelia of male efferent ducts [301]. On 
the contrary, its expression is strongly increased in many type of tumor, including 
gliomas/ependymomas, mesotheliomas, papillary/follicular carcinomas, as well as 
carcinomas of the bladder, uterine cervix, kidneys, esophagus, lungs, head and 
neck, breast, brain and many other [302]. 
CA IX expressed in malignant cells has no mutations and its cDNA sequence is 
identical to that of normal cells. Hence, the association of this enzyme with tumors 
is exclusively related to its expression [303]. In tumor context, the increase of CA IX 
expression can occur in different conditions. In response to hypoxia, in increased 
cell density circumstances [304] and, for specific cell types, in acid 
microenvironment and during glucose deprivation [305-307], HIF-1 binds hypoxia 
responsive elements (HRE), which are localized in CA9 gene promoter just in front 
of the transcription start site at position -3/-10, and induces transcription of CA9 
gene [304] (Figure VII). In addition, functional inactivation of VHL (von Hippel 
Lindau) tumor suppressor gene, a member of E3 ubiquitin-ligase complex involved 
in the degradation of O2-sensitive α-subunit of HIF-1, results in the hypoxia-
independent expression of HIF-1 and thus of CA IX [308]. 
In solid tumors, CA IX overexpression is associated with poor prognosis [309-312]. 
CA IX functions in tumor cells 
The prominent function of CA IX in the context of tumor microenvironment is the 
enzymatic catalysis. Isoform IX is one of the membrane bound CA isozymes whose 
catalytic domain is localized at the extracellular surface of the plasma membrane. 
This location of active site supports its role in controlling pH dynamics in solid 
tumors. CA IX is a peculiar member of CA family, in fact possesses several 
properties highly suitable for the tumor physiology. On the contrary to the other 
CA, isoform IX is insensitive to high lactate concentration found in the tumor [313], 
possesses the PG-like domain which enables it to function most efficiently at more 
acidic pH values typical of cancer mass [275, 292, 293], participates in the 
extracellular acidification [286] and regulates the intracellular pH [314]. 
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Extracellular hydration of CO2, indeed, results in the production of protons and 
bicarbonate. The first remains outside of the cells and increase the acidity of 
extracellular space, thus promoting tumorigenic transformation, chromosomal 
rearrangements, ECM breakdown, migration and invasion, protease activation and 
growth factor production [257, 315, 316]. In addition, acidic pHe can impair 
immune functions and influence the effect of conventional therapy on tumor cells, 
modulating the uptake of cancer drug [317]. 
The other product is transported inside the cells, where contributes to the 
production and the maintenance of alkaline pHi supporting cell survival and 
proliferation [317]. Vince and Reithmeier proposed that this transport could be 
mediated by a spatial and functional cooperation between bicarbonate 
transporter(s) and CA IX [318]. Subsequently, McMurtrie et al. showed that this 
cooperative complex (called “metabolon”) is present in various cellular/tissue 
contexts and that can include different combinations of transporters and CA 
isozymes (AE1-3, NBC and CA II, CA IV and CA IX) [319]. It is also to note that CA 
IX is able to regulate pHi homeostasis both in presence and absence of the key pHi 
regulating protein NHE1 [320]. 
Besides the control of CO2 metabolism, CA IX can directly participates to cell 
adhesion and migration both mediating the attachment of cells to solid support and 
competing with E-cadherin for the interaction with β-catenin, thus weakening cell-
cell contact [321, 322]. Recent studies showed that also the PG-like N-terminal 
extension of CA IX extracellular domain can mediate cell adhesion [323]. This 
region, in fact, contains a sequence similar to that of aggrecan attachment domain 
and thus may be capable of binding ECM components [289, 323]. Moreover, tumor 
cells silenced for CA IX are less able to form cancer mass in vivo. Tumor growth is 
further reduced when the knock-down of CA IX is combined with that of CA XII, 
suggesting a functional complementarity between the two isoforms [320]. 
CA XII and CA II 
Besides CA IX, other CA family members related to tumor biology are the isoforms 
XII and II. CA XII is a membrane-bound isozyme whose catalytic site is exposed at 
the cell surface; instead, CA II is a cytosolic isoform [283, 284]. CA XII is 
overexpressed in renal cancer cells [285, 324], breast cancer [325], and other many 
tumors [326]. This isozyme participates in the regulation of pHi and pHe and shows 
a complementary function compared to CA IX [320]. In fact, the knock-down of 
isoform IX results in up-regulation of XII one (at both mRNA and protein level) 
[257]. In breast cancer, CA XII has been shown to be a marker for good prognosis 
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[327], on the contrary, its spliced shorter variant seems to be a marker of poor 
prognosis in astrocytomas [328]. 
Unlike isoforms IX and XII, CA II is only weakly expressed in many tumors. 
Nevertheless, it is possible that, thanks to its high catalytic activity, is still able to 
participate in the maintenance of alkaline pHi and acidic pHe contributing to tumor 
growth and survival [257, 329]. Alternatively, it could perform its function at the 
level of tumor vasculature, where its expression is significantly higher than that of 
normal endothelium [330]. In the stomach, Pan et al. showed that knockout of CA 
IX leads to increase in CA II, and vice versa [331]. Although the reason why a 
membrane-bound isoform is compensated with a cytosolic one is intriguing, it is 
possible that both are able to interact with another protein by determining the 
formation of pH-regulating complex [257]. In order to clarify the function of both CA 
XII and CA II in the context of tumor microenvironment, further studies are 
required. 
Membrane transporters 
Other factors that contribute to pHi homeostasis in tumor cells are the isoform 1 of 
NHE [332, 333], MCTs and bicarbonate transporters (BTs), including NBCs, AEs 
and NDCBEs [334, 335]. NHE1 couples the export of H+ across biological 
membranes to the import of Na+, MCTs couple H+ export with that of 
monocarboxylates (lactate and pyruvate), NBCs translocate Na+ and HCO3- together 
in the same direction, AEs are responsible for Cl--HCO3- exchange, and NDCBEs act 
as Na+-dependent Cl--HCO3- exchangers but are expressed by a limited number of 
cell types. NHE1, NBCs, NDCBEs perform their function using the energy stored in 
the inwardly directed electrochemical Na+ gradient generated by Na+-K+ ATPase, the 
inward Cl- gradient, instead, provides the driving force for AEs activity [336]. BTs 
[337], MCTs [338], but especially NHE1 [333, 339-341] are important proteins for 
cytoplasmic alkalinization and have a role in cell migration and invasion. 
During migration and invasion processes, cancer cells change their morphology by 
acquiring the front-rear polarity and forming lamellipodia and invadopodia, 
respectively [342] (Figure IX). The polarization of tumor cells along their longitudinal 
axis is fostered by NHE1, which is linked to actin filaments and controls the 
organization of the cytoskeleton [339, 343-345], as well as contributes to cytosolic 
alkalinization and extracellular acidification [346-349]. In fact, during cell migration 
NHE1 [343, 346, 347], together with NBC1 and AE2 [351-353], accumulates at the 
leading edge (Figure IX). In this location, they mediate ions entry that, together with 
water influx across aquaporins (AQP1) [354], supports the outgrowth of the 
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lamellipodium [351-353]. In addition, they form the pH-regulating machinery which 
generates a pHi gradient from the front toward the rear part of cells. The neutral-
alkaline pHi at the leading edge promotes cofilin activity which, by severing actin 
filament (F-actin), generate free barbed ends providing sites for further actin 
polymerization and thus driving membrane protrusion [355, 356] (Figure IX). 
Recent studies showed that the “metabolon” previously described [318, 319] is 
formed also at the lamellipodia present in the front of the cells, where NBCs and 
AE1, -2, -3 establish a functional cooperation with CA IX, whose role is to produce 
bicarbonate and to maximize the rate of its transport across the plasma membrane 
contributing to increase pHi [357-359]. 
At the rear end, instead, gelsolin, activated by acidic pHi and high Ca2+ 
concentration, controls the length of actin filaments by its severing and capping 
activities [360-362]. Gelsolin, in fact, helps to recycle actin promoting the retraction 
of the rear end of a migrating cell [363]. 
Oppositely to the pHi gradient, the pericellular proton concentration within the 
glycocalyx, generated by the pH-regulating complex described above, is up to twice 
as high at the leading edge than at the rear part of migrating cells [347-349] (Figure 
IX). This pHe gradient coordinates the formation and release of focal adhesion 
contacts mediated by integrins with ECM or between cells. 
 
Figure IX. Role of protons in cell motility. pH homeostasis is crucial for tumor cells migration and 
invasion. BTs (including NHE1, NBC1, AE2), MCT4, AQPs and CA IX, accumulate at leading edge 
membranes and promote the cytoplasmic alkalinization and pHe acidification. pHi alkalinization 
activates cofilin, an actin-binding protein capable of increasing the recycling of actin monomers (globular 
actin, or G-actin) at the rear of “older” actin filaments (filamentous actin, or F-actin), thereby inducing de 
novo localized actin assembly, cytoskeleton reorganization and membrane protrusion. pHe acidification 
results in the modulation of integrin-mediated cell-matrix adhesion, thus facilitating cell migration. At the 
trailing edge, instead, alkaline pHi and acid pHe drive the retraction of the rear part of migrating cells 
[modified from ref. 336]. 
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Integrin-mediated interactions, indeed, are sensitive to proton concentration [347, 
349, 364-366]. At the leading edge, the extracellular acidification mediated by 
NHE1 facilitates the formation of focal adhesion contacts, stabilizes the existent 
ones [348, 349] and fosters the exocytosis and function of MMPs by inducing both 
them protonation or that of their substrates, thus promoting proteases activity 
[367, 368]. The alkaline pH of the rear edge, instead, weakens the adhesion to ECM 
or to neighbored cells [363] and increases the entry of Ca2+ into cells through the 
proton-sensitive TRPM7 channel promoting gelsolin activity [369]. Like NHE1, NBC1 
and AE2, also MCT4 accumulates at the leading edge, where export H+ and 
monocarboxylates, contributing to lowering the pHe [370] (Figure IX). 
Besides H+, the exported lactate may promote cell migration. It, in fact, up-regulates 
the synthesis of ECM components (such as hyaluronan and type I collagen) to 
which cells can adhere via a proton-sensitive mechanism, and thus migrate [371, 
372]. Lastly, it is important to note that as NHE1 is one of the most prominent 
proteins regulating pHi, it has also an important role in supporting cancer cells 
survival and proliferation. It has been demonstrated that both its pharmacological 
inhibition [373-375] and its lacking activity [376, 377] in cancer cells results in a 
drastic reduction of tumor growth in vivo. 
THE INTERCELLULAR COMMUNICATION 
In pluricellular organisms, intercellular communication is instrumental for the 
survival and the function of cells and to ensure the integrity of tissues. Typically, 
the exchange of informations occurs through the transmission of electrical or 
chemical signals. The first allows the diffusion of nerve impulse across electrical 
synapses, formed of gap junctions or nexus, which enable the free flow of ions from 
one cell to another. The latter is mediated by extracellular molecules, such as 
nucleotides, lipids, short peptides or proteins released by cells. These molecules 
bind to specific receptors on other cells and activate intracellular pathways, thus 
modifying their physiological state. Alternatively, cells can communicate with each 
other after direct cell-cell contact through mechanisms of nibbling, trogocytosis and 
nanotubes. The mechanism of nibbling concerns the unique ability of DCs to 
capture antigen from live cells by physically stripping large membrane fragments 
without inducing death of the donor cells [378]. The trogocytosis, instead, describes 
the transfer of plasma membrane fragments from one cell to another, triggered by 
receptor signaling following cell-cell contact without cell death induction [378]. It is 
an active and, in some circumstances, bidirectional process that, compared to other 
transfer mechanisms, occurs very quickly (within minutes after cell-cell 
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conjugation) [379, 380]. This phenomenon was mainly observed in cells of the 
immune systems, including B cells, T cells, NK cells, monocytes [381] and DCs 
[382]. It was documented that both MHC (major histocompatibility complex) class I 
and class II proteins can transfer from APCs to T cells [383-388], and that many 
other cell-surface molecules can be transferred, not only to T cells, but also to B 
and NK cells enabling the coordination of the immune response [389]. 
Another mode of cell contact dependent protein trafficking is mediated by the 
formation of membranous channels of 50-200 nm in diameter, called nanotubes, 
that connect cells over long distances [378]. These nanotubular connections, first 
described in cultured rat pheochromocytoma PC12 cells [390], are formed by many 
different cell types, such as T, B, NK cells, macrophages [385, 391-393], and 
between different cancer cells (breast and ovarian cancer cell lines) and stromal 
cells (mesenchymal stem cells and ECs) [394]. These structures allow intercellular 
transfer of organelles (such as mitochondria) [394], of various plasma membrane 
components, of cytoplasmic molecules [395], as well as of calcium ions, MHC class 
I, pathogens, small organelles of the endosomal/lysosomal system and ATP-Binding 
Cassette transporter [396-401]. 
The intercellular communication mediated by the exchange of proteins can occurs 
also by trans-endocytosis, a biological process documented, for instances, in Notch-
mediated signal between adjacent cells [402-404]. Notch is a transmembrane 
receptor involved in embryonic development and cell differentiation, and is formed 
by separable extracellular and intracellular domains linked together by non-
covalent bonds [405, 406]. During the process of trans-endocytosis, the part of the 
receptor present on the outer surface of a cells is cleaved off and undergoes 
endocytosis into its neighboring cell, where is transferred into endosomes. 
Simultaneously, the intracellular domain is released in the cytoplasm, translocates 
to the nucleus, and activates gene transcription [405, 406]. 
In addition to these mechanisms, another form of intercellular communication 
involves the secretion by cells of small extracellular membrane vesicles (EMVs) 
characterized of an approximately spherical structure limited by a proteolipid 
bilayer and containing bioactive components, such as numerous proteins, lipids 
and nucleic acids [407-411] as well as, in the case of larger vesicles, mitochondria 
[412]. These vesicles were observed first in 1978 by Friend et al. in cultures of 
spleen nodules and lymph nodes from a patient with Hodgkin's disease [413], and 
then in 1980 by Poste and Nicolson, who found that vesicles secreted by highly 
metastatic B16 mouse melanoma cells enable the poorly metastatic ones to 
metastasize to the lung [414]. 
Introduction 
32 
 
Subsequently, these vesicles were detected in the culture supernatant of different 
cell types both of hematopoietic origin (such as B cells [415], DCs [416, 417], mast 
cells [418], T cells [419] and platelets [421, 422]) and of non hematopoietic origin 
(as intestinal epithelial cells [423], tumor cells [424, 425], Schwann cells [426], 
neuronal cells [427, 428], astrocytes [429], ECs [430] and fibroblasts [141]). In 
addition, EMVs were found in vivo in diverse body fluids [431], including semen 
[432-434], blood [435], urine [436, 437], saliva [438], breast milk [439], amniotic 
fluid [440], ascites fluid [441-443], cerebrospinal fluid [444] and bile [445]. 
The identification of these numerous forms of intercellular communication supports 
the concept that “no cell is an island” [446]. All organisms, in fact, are composed by 
non-autonomous cells capable of interacting with each other thanks to a 
continuous horizontal exchange of informations. 
Structure and biogenesis of extracellular membrane vesicles 
Eukaryotic cells constitutively release heterogeneous populations of EMVs both in 
vivo and in vitro, which can be divided into two distinct subtypes, known as 
exosomes and microvesicles, characterized by different properties, including origin, 
size, morphology, buoyant density and protein composition. 
Exosomes 
Exosomes are membranous nanovesicles of 30-100 nm in diameter, with a rounded 
shaped morphology and a floating density of 1.10-1.21 g/mL in sucrose gradient 
[415, 447]. They arise as intraluminal vesicles (ILVs) in the endosomal 
compartments called multivesicular bodies (MVBs) by inward budding and pinching 
at the limiting membrane into the endosomal lumen [448], so they contain cytosolic 
components and expose the extracellular domains of transmembrane proteins, 
which thus maintain the same topological orientation as at the endosomal 
membrane [449, 450] (Figures X-a and X-b). Thereof, MVBs not only represent a late 
step in the maturation of endosomes to lysosomes (degradative MVBs), but also 
participate in an alternative process. These compartments, in fact, can fuse with 
the plasma membrane and release their segregated vesicles into the extracellular 
space (exocytic MVBs), where upon ILVs are called exosomes [407] (Figure X-a). 
Exosomes can originate from multiple cell types, thus their cargo contains both 
type-specific and common molecules. Examples of cell-type specific proteins are 
transferrin receptor [451] and integrin α4β1 [452] in exosomes released by 
reticulocytes; CD3 [451], integrin β2 and the ubiquitin ligase c-CBL [419] in T cell 
derived exosomes; A33 antigen and the cell-surface peptidase IV/CD26 [423] in 
exosomes originate by enterocytes. The molecules ubiquitous in exosomes derived 
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from distinct source, instead, are cytoskeletal proteins (tubulin, actin and actin-
binding proteins), molecules involved in the sorting of proteins/cargo, as ESCRT 
complex (endosomal sorting complex required for transport), chaperones (heat 
shock protein, as HSP70 and HSP90), proteins involved in signal transduction 
(protein kinase, 14-3-3 and heterotrimeric G proteins), clathrin, protein involved in 
transport and fusion (annexins and Rab proteins), several metabolic enzymes (such 
as peroxidases, pyruvate and lipids kinases and enolase-1), elongation factors and, 
perhaps, proteins that participate in some common exosomes functions not yet 
known [453, 454] (Figure X-c). 
According to their origin, exosomes do not contain any proteins derived from 
nucleus, mitochondria, endoplasmic-reticulum or Golgi-apparatus [455]. The 
process of protein sorting can be mediated by different mechanisms both ESCRT-
dependent and -independent. ESCRT machinery is composed of four proteins 
complexes (known as ESCRT-0, -I, -II, -III) associate with accessory proteins (Alix, 
VPS4 and tsg101): the ESCRT-0, -I and -II complexes are able to recognize and 
sequester the mono-ubiquitinated proteins at the limiting membrane of endosomes, 
instead the ESCRT-III complex acts in the budding and scission phases [456, 457]. 
On the contrary, the ESCRT-independent mechanisms include: the non-specific 
engulfment of small portions of cytosol, the transient association of proteins with 
the transmembrane ones [458] and a process dependents on raft-based 
microdomains, where ceramide formed from sphingolipids by neutral 
sphingomyelinase can induce the coalescence of small microdomains into larger 
ones, promoting domain-induced budding [459]. Alternatively, proteins can be co-
sorted in concert with other proteins, such as tetraspanins which are enriched in 
exosomes where cluster into membrane microdomains [460] (Figure X-b), or flotillin, 
stomatin and lyn, that are raft-associated proteins [461]. Presence of several sorting 
mechanisms may induce the formation of heterogeneous subpopulations of ILVs. 
The lipid composition of exosomes is similar to that of the plasma membrane of the 
producing cell [462], nevertheless in comparison to it, exosomes are highly enriched 
in cholesterol, sphingomyelin and hexosylceramides to the detriment of 
phosphatidylcholine and phosphatidylethanolamine [463-466]. In agreement with 
these observations cholesterol-rich MVBs secrete their vesicles cargo, on the 
contrary, the cholesterol-poor ones act as degradative MVBs [467]. 
Other components of exosomes are mitochondrial DNA (mtDNA) [468] small non-
coding RNAs, as miRNAs (known to control gene expression by regulating mRNA 
turnover), and mRNAs, which can be translated into proteins by recipient cells, 
each one can be cell-type specific [410, 469, 470] (Figure X-c). It is noteworthy that 
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not all mRNAs and miRNAs of a cell end up in exosomes. Their selective 
incorporation could be mediated by ESCRT-II, which acts also as RNA binding 
complex [471], by RISC (RNA-induced silencing complex) and its key components 
GW182 and AGO2 (argonaute), which are enriched in exosomes [472]. 
After that, ILVs were assembled, the secretory MVBs are transported toward the cell 
periphery, where fuse with the plasma membrane. Classically, intracellular 
trafficking and the fusion of compartments require the cytoskeleton (actin and 
microtubules), associated molecular motors (kinesins and myosins), molecular 
switches (small GTPase of the Rab family) and the fusion machinery [473]. 
The same effectors probably participate in the release of exosomes. Examples of Rab 
proteins involved in the mobilization event are: Rab11, engaged for Ca2+-induced 
exosome secretion by the K562 erythroleukemia cell line [474] (Figure X-a); Rab35, 
required for proteolipid protein (PLP)-enriched exosomes release by oligodendroglial 
cells [475]; Rab27a and Rab27b, which have a complementary role in spontaneous 
secretion of MHC class II-bearing exosomes by HeLa-CIITA cells [476], Rab27a, but 
not Rab27b, also acts in exosome secretion by different mouse mammary 
carcinoma [477]. In this contest, Rab proteins effect appears to be redundant and 
cell type dependent, alternatively, these proteins could act upstream of exosomes 
secretion. In fact, the selective inactivation of each of them only partially affects this 
process [475, 476]. 
Subsequently, the fusion of MVBs with the plasma membrane is probably driven by 
a specific protein machinery, which includes soluble factors (such as N-
ethylmaleimide-sensitive factor, NSF, and soluble NSF-attachment protein, SNAP), 
membrane complexes (such as SNAP-attachment protein receptor) and 
synaptotagmin family members [478, 479]. 
Several events can regulate exosomes production, among them, the increase of 
cytosolic Ca2+ concentration is one of the most trigger [474] (Figure X-a). In addition, 
DCs were stimulated to release exosomes as the result of the interaction with T 
cells, that recognize peptide-loaded MHC class II [480]; neuronal cells produce 
exosomes in response to plasma membrane depolarization; and cross-linking [427, 
481] of CD3 in T cells stimulates exosomes release by T cells [419]. The intracellular 
mechanisms of exosomes biogenesis and secretion are not yet clearly defined and 
future works are needed. Process understanding, in fact, represents an essential 
step to further identify exosomes function and significance. 
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Figure X. The generation and composition of exosomes. Membrane proteins are endocytosed via 
clathrin-coated pits, clustering of proteins in lipid rafts or tetraspanin-enriched membrane microdomains 
(TEMs). Then, they are addressed to early endosomes (EEs), those gradual maturation toward the late 
endosomes results in the increase of intraluminal vesicles number. These late endosomes are also known 
MVBs. The intracellular transport of these vesicles and their cargo selection are facilitated by 
ubiquitylation, Rab proteins and ESCRT machinery. MVBs can recycle proteins back to the membrane, 
evolve into lysosomes for degradation, or fuse their membrane with the plasma membrane thus releasing 
their intraluminal vesicles as exosomes. This last process is promoted by various stimuli, as Ca2+ flux 
and stress (a, b). The exosomes composition varies with the cell type, but includes some ubiquitous 
molecules, including Rab proteins, annexins and ARP2-ARP3, which are involved in membrane transport 
and fusion, adhesion proteins (as integrin and ICAMs), cytoskeleton proteins, tetraspanins and nucleic 
acids (c). The uptake of exosomes by target cells occurs by different mechanisms: these vesicles can bind 
to specific receptors (mainly phosphatidylserine receptors), interact unspecifically or fuse with the 
recipient cells membrane (d). ERM, ezrin-radixin-moesin; GPI, glycosylphosphatidylinositol; ICAM, 
intercellular adhesion molecule [420]. 
Introduction 
36 
 
Microvesicles 
Microvesicles (MVs) are membranous particles with irregular shape and constitute a 
larger and more heterogeneous populations in size compared to exosomes, ranging 
from 50 to 1,000 nm in diameter [407, 482]. Their buoyant density is not yet been 
determined, but may overlap that of exosomes [378, 483]. MVs, as well as 
exosomes, arise through an unconventional mechanism (i.e. not based on the 
classic signal-peptide secretory transport pathway) [484] but in contrast to the 
exosomes endocytic origin, they are formed through direct outward budding from 
the plasma membrane and fission of their connecting membrane stalks [431, 485-
487] (Figures XII and XIII). 
MVs formation is driven by the acquisition of membrane curvature which requires 
physical perturbations of the lipid bilayer [488]. These deformations seem to be 
mainly mediated by proteins and lipids, which can modify membrane shape 
through different mechanisms. First, cytosolic proteins recruited to the membrane 
can polymerize with an intrinsic curvature and thus impose it on the membrane 
[489-492] (Figure XI-a). In this model, the constraints induced by proteins can be 
supported by lipid aggregation into microdomains, which leads to membrane 
bending by beginning the budding process [493]. Second, proteins can cause 
morphological changes in cell membrane according to the bilayer-couple 
hypothesis. This theory, initially popularized by Sheetz and Singer in 1974, 
proposes that through the physical insertion of amphipathic moieties into one face 
of the lipid bilayer, proteins can increase the surface area of this leaflet and thus 
induce the spontaneous curvature of the bilayer [494-496] (Figure XI-b). 
Third, contractile proteins can add or remove tensile forces, stretch only one face of 
the lipid matrix and thus create a structural asymmetry that would cause bending 
[497]. Fourth, proteins can contribute to regulate the lipid composition and 
distribution within the plasma membrane both due to asymmetric lipid synthesis 
and owing their relocation [498, 499]. Aminophospholipid translocases, in fact, are 
proteins that regulate the transfer of phospholipids from one leaflet to the other in 
an ATP-dependent manner. In particular, flippases are translocases that move 
phospholipids from the outer face to the inner one; on the contrary, floppases 
perform phospholipid transfer in the reverse direction [500-502]. In this respect, the 
movement of phosphatidylserine to the outer leaflet promotes membrane budding 
and vesicles formation [503, 504] (Figure XI-c). 
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In addition, selective enrichment of cholesterol could decrease local membrane 
stiffness, alter the relative bilayer surface areas and promote the budding process 
[505-507] (Figure XI-d). Hence, MVs shedding occurs at specific locations, where 
particular proteins and lipids accumulate [508]. 
Once the bud is formed, it is physically separated from the plasma membrane of 
donor cells (the process known as fission) thanks to contraction of cytoskeletal 
structures by actin-myosin interactions [425, 509, 510]. In tumor cells, this phase 
starts with ADP-ribosylation factor 6 (ARF6), a small GTP-binding protein of Ras 
family expressed in all eukaryotes, which activates phospholipase D (PLD), that, in 
turn, recruits ERK (extracellular signal regulated kinase) to the plasma membrane. 
ERK is able to phosphorylate and activate MLCK (myosin light-chain kinase), a 
kinase that promotes myosin function, cytoskeleton contraction and thus the 
release of MVs [425] (Figure XII). Vesicles contraction seems to be internally, at the 
necks of the bud, in this location contractile proteins complete the fission process 
 
Figure XI. Mechanisms of membrane deformation mediated by proteins and lipids. Proteins that 
assemble with an intrinsic curvature could drive membrane shape (a). Membrane curvature according to 
the bilayer-couple hypothesis (b). Transfer of lipids to one leaflet (c) and/or selective enrichment of 
cholesterol (d) result in membrane curvature owing to bilayer surface-area discrepancy between the two 
leaflets. Black arrowheads indicate the transferred lipids in (c) and cholesterol in (d) [modified from ref. 
488]. 
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by acting like a drawstring [425, 508]. Besides translocases enzymes activity, also 
that of contractile proteins requires energetic input [508] (Figure XII). 
It is noteworthy that this signaling cascade does not affect exosomes release, 
supporting the concept that the biogenesis of these subtypes of vesicles involves 
distinct mechanisms [425]. 
MVs production is documented in resting cells, but the rate of this phenomenon 
becomes significantly higher in response to various stimulations, including 
increased in cytosolic Ca2+ concentration, cellular stress (such as DNA damage), 
cytokine exposure, anticancer drug treatment [511-515], and, for DCs, in response 
to LPS [417, 516] (Figure XIII). Since the release of MVs causes the removal of small 
portions of membrane from the cell surface, they must be continuously replaced. In 
resting cells, the maintenance of an appropriate surface area is favor by the 
constitutive traffic of membrane enriched in vesicles-specific molecules. On the 
contrary, surface area homeostasis in high rate shedding cells requires a further 
compensation mechanism. In these activated cells, in fact, vesicles formation seems 
occur in conjunction with the discharge of non-secretory exocytic vesicles stored in 
the cytoplasm, which allow to insert “new portions” of membrane in the cell surface 
[517, 518] (Figure XIII). 
Like exosomes, MVs cargo is composed of bioactive components from cytosol, such 
as nucleic acids (in particular miRNAs) [519, 520], lipids, numerous proteins 
(including cytokines, oncogenes, growth factor receptors, integrin receptors, 
proteases and/or MHC class I molecules) [521], whole intact organelles, such as 
 
Figure XII. The signaling cascade that regulates outward budding and fission of MVs. ARF6 
activates PLD, which recruits ERK to the plasma membrane. ERK, in turn, activates by phosphorylation 
MLCK, which phosphorylates and activates myosin light chain, thereby triggering the release of MVs 
[529]. 
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mitochondria [412] and infectious particles (as HIV, human immunodeficiency 
virus, and prions) [522-525]. Transmembrane proteins incorporated into MVs 
conserve the same topological orientation of the parent cell [521]. Since MVs are 
released by different cell types, their composition depends on the cell from which 
they originate and the status in which it is [408]. Protein and lipid components of 
MVs are not random but selectively sorted at the cell surface, among them, there 
are also the proteins contained and trafficked via the ARF6-regulated endosomal 
recycling pathway, but compared to the mechanisms involved in exosomes 
biogenesis, these processes are less defined [526, 527]. However, the understanding 
about the structure and the biogenesis, not only of MVs but also exosomes, are not 
yet complete. In fact, despite the different origin, size, morphology, buoyant density 
and protein composition, MVs and exosomes derived from the cell cultures 
supernatant are not easy to separate because the size range overlap between the 
two different vesicles and also small vesicles (100 nm in diameter) may bud from 
the cell surface [528]. Finally, there is no general consensus as to the best method 
to isolate the two subpopulations. 
Functions of extracellular membrane vesicles 
Initially it was thought that vesicles observed in the cell culture supernatant were 
cell debris formed during the processes of apoptosis or necrosis in response to 
damage, or merely membrane fragments artificially released upon in vitro cell 
 
Figure XIII. Generation of MVs. MVs (red membrane) directly shed from the plasma membrane of cells 
in the resting state or, with a higher rate, from cells activated in response to various stimuli (such as the 
increase of cytosolic Ca2+ concentration and cellular stress, represent as a thunderbolt in the extracellular 
space). The cargo of microvesicles (gray) is sorted out from the cytosol. MVs release, i.e. the removal of 
membrane fragment at the cell surface, is compensated by a concomitant input of membrane delivered 
through the non-secretory exocytic vesicles stored in the cytoplasm (blue membrane) [407]. 
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handling [530]. Nowadays, the identification of some molecular mediators of 
biogenesis processes, as well as of certain conditions capable of increasing the 
production of vesicles, in addition to the findings that EMVs do not contain a 
random array, but a specific set of proteins both in the membrane and in their 
inside, allowed to assert that EMVs are actively secreted by live cells and could 
represent a new type of intercellular messenger [531-535]. 
In fact, once in the extracellular environment, exosomes and MVs could participate 
in a wide variety of physiological as well as pathological processes. The functions of 
EMVs are the result of their interactions with recipient cells and are related to their 
cargo and to their structural and biochemical properties, which, in turn, depend on 
their source of origin [378, 536]. Several modes of interaction of EMVs with target 
cells have been proposed. EMVs may dock at the plasma membrane of recipient 
cells through lipids or ligands-receptor interactions [537] (Figures X-d and XIV-a). 
For example, intracellular adhesion molecule 1 (ICAM1)-bearing exosomes secreted 
from mature DCs are captured by CD8+ DCs with help of lymphocyte function-
associated antigen 1 (LFA-1) [538] (Figure X-c). Similarly, galectin-5 participates in 
the recruitment of reticulocyte exosomes by macrophages [539]. 
The binding is followed by different events. First, at this location MVs can establish 
a reaction platform, thus inducing the extracellular assembly of functional 
multimolecular complexes and the coordinate development of multi-signaling 
processes [540, 541]. Second, EMVs can directly fuse with the plasma membrane of 
target cells, resulting in the integration of their membrane proteins into the 
membrane of recipient cells and the release of their cargo into the cytoplasm 
(Figures X-d and XIV-b). Third, vesicles can be internalized by endocytosis [378, 542] 
(Figure XIV-c). This event can be followed by: the fusion of endocyted vesicles with 
the limiting membrane of the endosome, which causes the release of vesicles 
contents into the cytoplasm and the incorporation of the membrane proteins into 
the endosomal membrane, which, then, can be redirected to the cell surface (Figure 
XIV-c-ii); the degradation of vesicles in the phagocytic pathway, which, for example, 
can lead to the production of antigenic peptides and their presentation onto MHC 
class II and I molecules at the cell surface [378, 407] (Figure XIV-c-iii); transcytosis, 
in fact, it has been documented that, at least MVs, once segregated within 
endosomes, can be released intact back to the extracellular space [407] (Figure XIV-
c-i). 
In addition, upon release from their cell of origin, vesicles could not remain intact 
for long, but broken down and release their contents in the extracellular 
environment, thus depositing paracrine signals. 
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For example, shedding vesicles derived from tumor cells release MMPs and their 
inducer (CD147 or EMM-PRIN, extracellular matrix metalloproteinases inducer), 
that, through the degradation of ECM, promote the motility of malignant cells, 
which become capable to invade tissues more quickly [543-545]. The vesicles shed 
from neurons, astrocytes, hepatocarcinoma and endothelia, instead, release FGF2 
[428, 429, 546]. Taraboletti et al. showed that EVMs derived from ovarian 
carcinoma cell lines burst is promote when the extracellular pH is acidic [547]. 
Further, this mechanism allows the regulated release by cells of proteins deprived 
of signal sequences, which, for this reason, can not enter the classical secretory 
pathway [407]. 
It also has been observed that vesicles secretion could be used to eliminate proteins 
resistant to lysosomal degradation. For example, during the process of red blood 
cell maturation, reticulocyte releases exosomes to remove membrane proteins no 
more necessary for its function, such as transferrin receptor [548]. 
Given that most of EMVs studies have been performed in vitro or from body fluids, 
their overall biological relevance remains unclear. 
 
Figure XIV. Interactions of MVs with their recipient cells. Once MVs are released by donor cells into 
the extracellular space they can: bind to the surface of the target cells by specific receptors (a); fuse their 
membrane with that of recipient cells (b); be internalized by endocytosis (c). This last event can be 
followed by: transcytosis (i); the fusion of MVs membrane with that of cell endosome (ii); the targeting to 
lysosome for the degradation of their contents (iii). The arrows indicate the direction of cargo discharge 
taking place upon vesicles membrane fusion [modified from ref. 407]. 
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EMVs in tumor diseases 
Besides the direct cell-cell contact and the secretion of bioactive molecules [549], 
the communication and the exchange of informations between cancer cells and the 
activated stroma can be mediated by the release of EMVs [550]. These vesicles 
contribute to the mutual horizontal transfer of tumor suppressors, 
phosphoproteins, proteases, growth factors, nucleic acids and bioactive lipids [551], 
all of which can modulate several phases of tumor progression, such as immune 
surveillance, inflammation, angiogenesis, thrombosis, invasion, metastasis, 
chemoresistance and further important biological events [408, 552-561]. Tumor 
cells may release various forms of membrane vesicles, each one characterized by 
unique morphological traits and functions [562]. They include exosomes, 
microvesicles [563] and a particular form of larger particles (called large oncosomes, 
1,000-10,000 nm in diameter) which shed from the plasma membrane of certain 
types of cancer cells during the amoeboid motility [564]. 
In the tumor microenvironment, tumor-derived vesicles can promote cancer cells 
survival, aiding the escape from apoptosis as well as from immune surveillance. 
MVs represent a protective mechanism from cell death because they serve as a 
means to remove the potentially dangerous caspase 3. In fact, MVs contain 
considerable amounts of this effector of apoptosis, which, for this reason, is not 
detectable within the cells [565, 566]. In addition, Shedden et al. showed that 
chemoresistant cancer cells express more membrane shedding-related genes 
compared with chemosensitive counterpart, suggesting a link between vesicles 
secretion and multidrug resistance [512]. The modulation of the immune system 
activities, instead, is mediated both through the mechanism of “complement 
resistance” [567] and by the suppression of the immune response. Shedding 
vesicles can contain the complement inhibitor membrane cofactor protein CD46, 
which inactivates the complement complex, hence avoiding cell lysis [568], as well 
as can express immune modulatory molecules. In particular, MVs from different 
types of cancer cells expose the ligand (FasL, CD95L) of the death receptor Fas 
(CD95), which induces apoptosis in activated T cells and diminishes their killer 
activity [569, 570]. Lymphoblastoma-derived microvesicles, instead, express latent 
membrane protein-I (LMP-I), which inhibits leucocyte proliferation [571]. Vesicles 
produced by human melanoma or colorectal carcinoma cells are also able to fuse 
with plasma membrane of monocytes, thus impairing their differentiation to APCs, 
but promoting the release of immunosuppressive cytokines, whose role is to block 
cytolytic T-cell activation and function [572]. 
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Further, tumor-derived vesicles can support invasive growth and metastasis of 
cancer cells with different mechanisms. First, MVs contain and expose proteases, 
including MMP-2, MMP-9, MT1-MMP, their zymogens, uPA and EMM-PRIN, that, as 
reported above, degrade numerous components of the ECM, allowing malignant 
cells to cross the basement membranes [425, 547, 573-575]. 
Second, tumor cells, but maybe also endothelial cells, monocytes and platelets, can 
produce procoagulant tissue factor (TF)-bearing MVs [576-578], which perform their 
function through coagulation-dependent and -independent mechanisms. In the 
former, TF-bearing MVs begin the intravascular coagulation and lead to fibrin 
production, which, in turn, can coat tumor cells protecting them from immune 
detection and attacks, as well as provides the structural support necessary for 
angiogenesis [579-581]. In the last, TF expressed by vesicles induces the paracrine 
activation of ECs through a specific class of G-protein-coupled receptors, known as 
PARs (protease-activated receptors), causing the increased secretion of the pro-
angiogenic heparin-binding EGF-like growth factor (HB-EGF) by these cells [582]. 
Third, tumor-derived vesicles can transfer mutant molecules to non-malignant and 
normal cells, thereby influencing their phenotype and biological behavior. It has 
been documented that the vesicles-mediated passage of oncogenic EGF receptor 
(EGFR or EGFRvIII) from aggressive glioma cells to indolent ones leads to 
morphological transformation of these recipient cells and increases their anchorage-
independent growth capacity [583]. Similar findings were reported by Peinado et al., 
who found that highly metastatic melanoma produces EMVs containing MET. This 
tyrosine kinase is able to increase the metastatic behavior of primary tumors by 
permanently re-educating the recipient bone marrow-derived cells (BMDCs) that, 
once activated, support the formation of pre-metastatic niches in distant organs 
[561]. 
Nucleic acids are also packaged in tumor-derived microvesicles and contribute to 
the transfer of genetic informations between cells. MVs contain: miRNAs, that may 
modify the transcriptome of recipient cells promoting tumor progression and 
metastases, but the mechanisms are not yet completely understood [469, 584-586]; 
noncoding RNAs (ncRNAs), that are involved in gene regulation at both 
transcriptional and post-transcriptional levels [587]; retrotransposon RNAs, such as 
LINE-1, HERV-K and Alu [411], that, by inserting themselves into the genome, can 
increase its plasticity [588]; cDNAs and genomic DNA derived from DNA replication, 
although their source is not fully clear [411]; mRNAs that promote tumor growth, 
invasion, immune repression [469] and angiogenesis [589]. 
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For example, cancer cell-derived MVs can transfer mRNA encoding growth factor 
(including VEGF and HGF) to monocytes, which then produce these molecules [520, 
590]. 
The protein, lipid and RNA contents of tumor-derived vesicles can be modified by 
different types of stressors typical of tumor microenvironment, such as hypoxia 
[591-593], acidosis [594], oxidative stress [595-597], thermal stress [596, 598, 599], 
radiation [591], shear stress [600] and cytotoxic drugs [601]. Accordingly, thermal 
and oxidative stresses induce leukaemia/lymphoma T and B to produce exosomes 
enriched in natural killer group 2, member D (NKGD2) ligands, which decrease the 
capacity of immune system to kill target cells [596]. Further, the treatment of 
aggressive B-cell lymphoma cells with chimeric anti-CD20 monoclonal antibody 
(rituximab) leads to the production of CD20-bearing exosomes, which act by 
protecting cells from antibody and complement-dependent cytolysis [602]. 
Melanoma cells cultured in acidic milieu, instead, generate exosomes enriched in 
ganglioside GM3 and sphingomyelin increasing the rigidity of their membrane. This 
alteration of lipid composition enables the exosomes to fuse more efficiently with 
the plasma membrane of recipient cells [594]. As for proteins and lipids, also RNA 
content seems to be stress-mediated. For example, exposure of breast cancer cells 
to hypoxia results in secretion of exosomes enriched in miR-210 [593]. However, 
further analysis will be necessary to elucidate how stress conditions modulate RNA 
content of tumor-derived vesicles. Intriguingly, alterations in the protein, lipid and 
RNA composition can cause change in the biological functions of vesicles, but their 
impact on tumor development needs to be clarified [603]. 
Besides cancer cells, the activated stroma (macrophages, fibroblasts and platelets) 
may release EMVs into the tumor microenvironment [551]. In particular, platelet-
derived MVs stimulate mRNA expression of pro-angiogenic factors in cancer cells 
[598] and, as mentioned above, fibroblasts-derived exosomes induce breast cancer 
cell migration and invasiveness through the Wnt-PCP signaling [141]. 
EMVs released by both cancer and stromal cells can perform their function locally 
(in the tumor microenvironment), as well as at the systemic level owing to their 
dissemination through body fluids (such as blood and urine), suggesting that the 
detection of these vesicles could be used as circulating non-invasive biomarkers not 
only for the early diagnosis [437, 469], but also in the surveillance of disease 
progression, and thus for prognosis [605-607]. In addition, EMVs may have other 
multiple applications. Because the release of vesicles can promote tumor 
development, the production and secretion processes themselves could also be an 
interesting target of anti-cancer therapy [608]. 
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Further, EMVs could be used as drug-delivery vehicles [609] or as adjuvant anti-
cancer treatment. In fact, cancer cell-derived MVs may facilitate immune attacks by 
transferring tumor antigens to APCs, which in turns activate T cells [424], 
alternatively, autologous dendritic cells-derived MVs, which act by triggering 
cytotoxic T lymphocytes in vivo, may be used as autologous anti-cancer 
immunotherapy [454, 610-614]. Finally, because the anti-cancer therapy modulates 
the contents of vesicles, the effectiveness of this treatment can be assessed by 
analyzing vesicles themselves [615]. 
Other functions of EMVs 
EMVs represent a new way of communication shared by an increasing number of 
cell types. In particular, APCs-derived exosomes express MHC-peptide complexes 
which are able to be directly recognized by their cognate T-cell receptor and activate 
primed CD4+ and CD8+ T cells [415, 616-618]; on the contrary, exosomes must be 
captured by DCs to induce the activation of naïve T lymphocytes [619]. This 
different behavior may depend on the activated conformation of LFA-1 integrin at 
the surface of DCs and primed (but not naïve) T lymphocytes, which efficiently bind 
to ICAM1-bearing exosomes [538, 617]. Alternatively, the activation of naïve T cells 
may require not only the TCR-dependent signal, but also the cytokines secreted by 
DCs [530]. As with APCs-derived exosomes, those released by B cells display MHC 
class I and class II, which activate specific T cell responses [451], and functional 
integrins, that mediate the anchorage to ECM components and to cytokine-
activated fibroblasts. For example, exosomes adhesion to TNF-α-activated 
fibroblasts results in cytosolic calcium changes [620]. 
In addition, exosomes were secreted by epithelia both from the apical and the 
basolateral sides of the polarized cell monolayers. Exosomes released at the apical 
membrane contain specific molecules, such as syntaxin 3, microsomal dipeptidase 
CD26 and may be involved in a clearance process [451]. Basolateral exosomes, 
instead, are constitutively enriched in A33 antigen and MHC class II after activation 
by IFN-γ, and seem participate in antigen presentation [621]. 
Further, vesicles released from intraocular epithelia in response to inflammation 
contain the target antigen hr44 and CD63 and have a role in the maintenance of 
ocular immune privilege [622]. Further, cauda epididymal region produce exosomes 
[623], known as “epididymosomes”, that participate in sperm epididymal 
maturation by transferring P25b, a component of a family of sperm surface proteins 
necessary for the binding to the surface of the egg [451]. Recent reports showed 
that ECs produce exosomes enriched with miR143/145, which are transferred to 
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smooth muscle cells (SMCs), influencing gene expression of miRNA target and thus 
providing atheroprotective properties [624]. 
Although there are several evidences of the potential biological function of EMVs, to 
date, most of the studies were performed in vitro or from body fluids and the 
knowledge about their possible function in vivo is still very little. Furthermore, it is 
not clear if the amounts of EMVs used in in vitro experiments are comparable to 
those in vivo. In this regard, only one study was conducted. In 2006, Taylor et al. 
showed that the serum of women delivering the pregnancies at full term has higher 
concentration of placenta-derived exosomes compared to women delivering preterm, 
and that these vesicles express significantly higher levels of biologically active 
molecules, such as FasL and MHC class II. These vesicles are able to inhibit T cell 
responses in a CD95L-dependent manner and this inhibition is greater with vesicles 
obtained from the serum of women delivering at term, suggesting that the function 
of these vesicles is to prevent the maternal immune response against the fetus 
[625].
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MATERIALS AND METHODS 
Cell cultures 
Human prostatic cancer cells (PC3 and DU145) and A375 human melanoma cell 
line were purchased from European Collection of Cell Culture (ECACC). Human 
dermic fibroblasts (HDFs) are from InvitrogenTM Life Technologies and NIH-3T3 
mouse fibroblasts are from Istituto Zooprofilattico Sperimentale della Lombardia e 
dell'Emilia-Romagna. Healthy (HPFs) and transformed (CAFs) human prostatic 
fibroblasts were isolated from surgical explantation of patients who signed informed 
consent in accordance with the Ethics Committee of Azienda Ospedaliera 
Universitaria Careggi by Prof. Serni of Dipartimento di Medicina Sperimentale e 
Clinica/Urology (Firenze, Italy). Cells were routinely cultured in Dulbecco's Modified 
Eagle's Medium (DMEM) supplemented with 2 mM glutamine, with penicillin (100 
U/mL) and streptomycin (100 µg/mL), and with 10% fetal bovine serum (FBS, 
Euroclone). Cells were incubated at 37°C in a humidified atmosphere of 5% CO2-
95% air. 
Materials 
Unless otherwise specified all reagents are from Sigma/Aldrich. Carboxyfluorescein 
diacetate succinimidyl ester (CFDA-SE), Opti-MEM and Lipofectamine® transfection 
reagent are from InvitrogenTM Life Technologies. Polyvinylidene difluoride (PVDF) 
membrane and Immobilon Western Chemiluminescent HRP Substrate are from 
Millipore. Boyden chambers were purchased from Euroclone. Cocultures separation 
was performed by MACS MicroBeads and MACS Column Technology patented by 
Miltenyi Biotec. Apoptosis test is performed by Annexin-V-Fluos staining kit from 
Roche. Sodium [14C] bicarbonate, L-amino acids mixture [14C] and the storage 
phosphor screen are from Perkin Elmer. 2D Quant kit, Ettan™ IPGphor™ system, 
IPGphor Cup Loading Strip Holders and the ECL plus immunodetection system 
were purchased from GE Healthcare, USA. ReadyStrip™ IPG strips were purchased 
from Bio-Rad. CA IX siRNA, anti-enolase and anti-actin antibodies were purchased 
from Santa Cruz Biotechnology. Anti-glyceraldheyde-3-phosphate dehydrogenase 
(GAPDH) and anti-superoxide dismutase 2 (SOD-2) antibodies were from Abcam, 
anti-β-tubulin was from Sigma/Aldrich, anti-pyruvate kinase M1 (PKM1) was from 
Proteintech, anti-pyruvate kinase M2 (PKM2) was from Cell Signaling Technology, 
anti-vimentin was from Thermo, anti-CA IX was from Bioscience Slovakia. 
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Proliferation assay 
The proliferation was evaluated using CFDA-SE. Tumor or stromal cells were 
labeled with the dye at the concentration of 2.5 µM. Then PC3, DU145 or fibroblasts 
were cultured alone or in coculture for 40 hours. After that the cells were detached, 
fixed in 3% paraformaldehyde and analyzed by flow cytometry. The fluorescence 
value obtained was analyzed by ModFit software to estimate the proliferation index. 
Fluorescence analysis of protein transfer 
The transfer of proteins from donor cells to recipient cells was evaluated by using 
CFDA-SE. Donor cells were labeled with the dye at the concentration of 10 µM and 
then plated in coculture with recipient cells. For flow cytometry analysis the cells 
were detached after 24 or 40 hours, fixed in 3% paraformaldehyde and the ability of 
donor cells to transfer proteins was evaluated by measuring the value of 
fluorescence intensity increase of recipient cells, which is obtained from the ratio 
between the fluorescence value of the recipient cells measured after coculture with 
donor cells and the autofluorescence of recipient cells. In fact, once that CFDA-SE 
passively diffuses into the cytoplasm of donor cells, intracellular esterases cleave its 
acetate groups and the probe is converted to the fluorescent ester, called CFSE. 
CFSE reacts with intracellular amines (including that of proteins) and forms 
fluorescent conjugates that are retained within the cells. For this reason, when 
labeled donor cells transfer their proteins to recipient ones, the fluorescence 
intensity of recipient cells increases, on the contrary, if the passage of fluorescent 
proteins does not occur, their fluorescence intensity remains close to that of 
autofluorescence. 
For confocal microscopy analysis the coculture was grown on glass coverslips. 
Immediately after plating and after 6 hours the cells were washed with phosphate-
buffered saline (PBS) and fixed in 3% paraformaldehyde for 20 minutes at 4°C. After 
that, the cells were washed again in PBS, mounted with glycerol plastine and 
observed by confocal fluorescence microscopy (Leica TCS SP5). 
Analysis of lipid transfer 
The transfer of lipids from donor cells to recipient ones was evaluated by using 
CellVue®. Donor cells were labeled with the dye according to the manufacturer’s 
protocol and then plated in coculture with recipient cells on glass coverslips. 
Immediately after plating and after 6 hours the cells were washed with PBS and 
fixed in 3% paraformaldehyde for 20 minutes at 4°C. After that, the cells were 
washed again in PBS, mounted with glycerol plastine and observed by confocal 
fluorescence microscopy (Leica TCS SP5). 
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Conditioned media preparation 
Tumor cells were grown in starvation medium for 48 hours, after that the medium 
was recovered, centrifuged at 1,000 xg for 20 minutes to discard cell debris and 
used to culture fibroblasts for 24 hours. Soon after the activation, fibroblasts were 
used for the experiments. 
Alternatively, CAFs were grown in starvation medium for 48 hours, after that the 
medium was recovered, centrifuged at 1,000 xg for 20 minutes to discard cell debris 
and used for the proliferation experiments of tumor cells. 
Acidification assay 
The pH of the external medium of tumor cells or fibroblasts either in single cultures 
(2x105 cells) or in cocultures (105 fibroblasts and 105 DU145 or PC3) was 
determined after 24 hours in DME supplemented with 1 mM sodium bicarbonate 
(pH 7.6) at atmospheric CO2. 
Cell death determination 
105 DU145 or PC3 were plated in DME supplemented with 25 mM hepes and 10 
mM sodium bicarbonate at pH 6.8, pH 7.4 and pH 8.0 for 40 hours at 5% CO2. 
Cells were detached with Accutase and labeled with Annexin-V-Fluos staining kit. 
The probe was directly detected by flow cytometry analysis. 
In vitro 2D tumor migration assay 
DU145 cells were grown to confluence, starved overnight at pH 6.8 or pH 8.0 in 
DME supplemented with 25 mM hepes and 10 mM bicarbonate at 37°C and 5% 
CO2. A wound was made with a sterile micropipette tip. Floating cells were removed 
by washing with PBS and then fresh DME at pH 6.8 and pH 8.0 + 10% FBS was 
added. Cells were photographed immediately after the wound initiation and after 18 
hours using an inverted Nikon Eclipse TS100 microscope (X10 objective) with Nikon 
Digital Sight camera system. 
In vitro 3D tumor migration assays 
5x104 green fluorescent protein (GFP)-expressing PC3 cells (PC3-GFP) were seeded 
in the top of Boyden chamber (trans-well migration assay) in serum-free medium 
alone or in coculture with 5x104 fibroblasts, while medium + 10% FBS was placed 
in the well below in 24-well tissue culture plates. After 18 hours, while the insert 
was still moist, the non-migratory cells were mechanically removed from the interior 
of the insert using a cotton swab. Migrated cells were photographed immediately by 
fluorescence microscopy (Leica TCS SP5). 
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In addition, PC3 migration was monitored by xCELLigence Real-Time Cell Analyzer 
(RTCA) DP instrument (Roche Applied Science). 5x104 PC3 were plated in serum-
free medium into the upper chamber of CIM (cellular invasion/migration)-Plate 16, 
while medium supplemented with 10% FBS was placed in the well below. As cells 
migrate from the upper chamber to the bottom one, they contact and adhere to the 
electronic sensors on the underside of the microporous PET membrane of the 
Boyden-like chamber, resulting in an increase in impedance. The impedance 
increase correlates to increasing numbers of migrated cells on the underside of the 
membrane and is continuously recorded by the RTCA DP instrument. The 
impedance is displayed as a dimensionless parameter termed “cell index”. 
Cocultures separation 
DU145 or PC3 were labeled with CFDA-SE and then plated in coculture with 
fibroblasts. For the CA IX expression analysis, after 40 hours cells were detached 
with Accutase and separated according to the manufacturer’s protocol of MACS 
Column Technology. A fraction of each cell sample was used to determine the 
separation efficiency by flow cytometry, which detects the percentage of CFDA-SE-
labeled tumor cells in fibroblasts sample after separation, and vice versa. The other 
part of the sample, instead, was lysed with 2-fold concentrated Laemmli 
electrophoresis buffer [627] without β-mercaptoethanol and bromophenol blue. 
For radiolabeling experiments the cells were detached, separated according to the 
manufacturer’s protocol of MACS Column Technology and the two cell populations 
recovered were counted with Bürker chamber. After that a fraction of each cell 
sample was used to determine the separation efficiency by flow cytometry, another 
fraction was used to measure the radioactivity (CPM, counts per minute) by liquid 
scintillation counter (Perkin Elmer), and, only for the samples subjected to 2D 
electrophoresis (2DE), a part was lysed and the proteins were opportunely 
extracted. The percentage purity of donor and recipient cells after the coculture 
separation was higher than 98%. The CPM values measured for recipient cells were 
calculated subtracting the radioactive contamination due to donor cells, and vice 
versa. 
Analysis of CA IX expression 
Cells were lysed with 2-fold concentrated Laemmli electrophoresis buffer [627] 
without β-mercaptoethanol and bromophenol blue and protein concentration was 
evaluated by bicinchoninic acid (BCA) assay. After that, samples were precipitated 
according to methanol/chloroform protocol [626]. Briefly, for about 150-300 µg of 
proteins contained in 150 µL of sample were added 600 µL of methanol, 150 µL of 
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chloroform and 450 µL of water, after each addition the sample was mixed by 
vortexing. Then the sample was centrifuged at 13,500 xg for 10 minutes, discarded 
the upper phase, kept the white precipitation disc evident between the upper and 
lower phases, and then 450 µL of methanol was added to the sample. After 10 
minutes of centrifugation at 13,500 xg the supernatant was discarded and the 
pellet was dried in a vacuum centrifuge for 20 minutes. Then, the sample was 
resuspended in Laemmli electrophoresis buffer [627]. The proteins (40 µg for each 
sample) were separated by SDS-PAGE, transferred on PVDF membrane by Western 
blot and probed with anti-CA IX antibody, and with anti-actin antibody as loading 
control. Immunoblots were incubated in PBS supplemented with 5% bovine serum 
albumin and 0.05% Tween for 1 hour at room temperature with primary antibody 
and then in PBS supplemented with 1% bovine serum albumin and 0.05% Tween 
for 45 minutes with secondary antibody conjugated with horseradish peroxidase 
(HRP). Development was performed with Immobilon Western Chemiluminescent 
HRP Substrate and chemiluminescence was detected by UVP (Ultra-Violet Products) 
Ltd Chemidoc-it 500 Imaging System. Quantitative analysis of the spots was carried 
out by Kodak MI software. 
Purification of membrane vesicles secreted by CAFs 
The culture supernatant recovered from radioactively labeled CAFs was centrifuged 
at 1,000 xg for 20 minutes to discard cell debris. The supernatant was then 
centrifuged at 10,000 xg for 40 minutes. The pellet was resuspended in PBS and 
centrifuged again at 10,000 xg for 40 minutes. The supernatant was recovered and 
centrifuged at 100,000 xg for 90 minutes. The pellet was resuspended in PBS and 
centrifuged again at 100,000 xg for 90 minutes. 
Serum present in fibroblasts growth medium was previously deprived of exosomes 
by centrifugation at 100,000 xg for 90 minutes. 
For proliferation experiments, “10,000 xg pellet” was resuspended in starvation 
medium and used to grow DU145. For electrophoresis and Western blot analysis, 
instead, both the “10,000 xg pellet” and the “100,000 xg pellet” were suspended in 
100 µL of 2-fold concentrated Laemmli electrophoresis buffer [627] (without β-
mercaptoethanol and bromophenol blue) and assayed for protein content by the 
BCA method. 40 µg aliquots from each sample were additioned with β-
mercaptoethanol and separated by SDS-PAGE. Subsequently gels were 
electroblotted onto PVDF membranes for detection or stained with colloidal blue 
coomassie. The stained gels were dried on a Slab Gel Dryer (Hoefer, model CD 
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2000). Dried gels and a storage phosphor screen were inserted in an exposure 
cassette. 
After a 15 days exposure time, the images were acquired on a Cyclone Storage 
Phosphor Scanner (Perkin Elmer). The blots were incubated with anti-enolase, anti-
β-tubulin, anti-GAPDH, anti-PKM1, anti-PKM2, anti-vimentin, anti-SOD-2 and 
anti-actin. After incubation with secondary antibodies, the blotting was developed 
by using the ECL plus immunodetection system and visualized by autoradiography. 
Dynamic Light Scattering analysis 
Membrane vesicles secreted by fibroblasts were purified as previously described, 
and resuspended in 800 µL of sterile PBS, after that their size distributions were 
obtained using Zetasizer Nano S Dynamic Light Scattering device and analyzed by 
the DTS software (Malvern Instrument Ltd). The analysis was performed at 25°C. 
Sodium [14C] Bicarbonate incorporation 
DU145 were plated in DME supplemented with 25 mM hepes, 10 mM sodium 
bicarbonate, 20 µM sodium [14C] bicarbonate (50.8 mCi/mmol) and 10% FBS at pH 
8.0 for 24, 48 and 72 hours. The medium was changed every day. The cells were 
lysed in 2-fold concentrated Laemmli electrophoresis buffer [627] without β-
mercaptoethanol and bromophenol blue. Protein concentration was evaluated by 
BCA assay. CPM values were obtained by scintillation counter (Perkin Elmer). 
[14C] L-amino acids incorporation 
Fibroblasts were cultured for 72 hours in exosomes-deprived complete medium 
supplemented with a mixture of [14C] L-amino acids. After that cells were detached, 
washed twice in starvation medium by centrifugation at 1,000 xg for 10 minutes, 
and plated in coculture with tumor cells. 
GC-MS measurements 
DU145 were plated in single culture and in coculture with fibroblasts in a 1:2 ratio 
in DME supplemented with 25 mM hepes and 25 mM sodium carbonate-13C (pH 
8.0) at 5% CO2. The medium was changed every day. After 40 hours DU145 cells of 
single culture and DU145 cells separated from CAFs with MACS Column 
Technology were lysed in 100% cold (-80°C) ethanol. Ethanol soluble fraction was 
dried in a vacuum centrifuge. Dried cell extracts were redissolved in 100 µL of 
ethanol containing 1% acetic acid. The solution was transferred in a microvial, 
taken to dryness under a gentle stream of nitrogen at room temperature and then 
derivatized with N-methyl-N-(t-butyldimethylsilyl)trifluoroacetamide in the presence 
of 1% t-butyldimethylchlorosilane for 2 hours at 80°C. 
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The samples were analyzed on an Agilent GC-MS system composed by a 7820A gas 
chromatograph coupled to a 5975B mass spectrometer operating in electron 
ionization (EI, 70 eV) mode (Agilent Technologies Italy, Cernusco sul Naviglio, Milan, 
Italy). The system was equipped with an automatic liquid sampler. The column was 
a DB 5 MS, 20 m, 0.18 mm, 0.18 µm film thickness (J&W, Agilent Technologies); 
helium was the carrier gas, at 0.7 ml/min constant flow rate. The oven temperature 
program was as follow: from 150°C to 220°C then at 5°C/min, then at 30°C/min to 
310°C, maintained for 3 minutes. The injections were performed in split mode (4:1 
split ratio); the injection volume was 1.5 µL. The injector port and transfer line 
temperatures were 260°C and 280°C, respectively. The ion source operated at 
230°C, while the quadrupole temperature was 150°C. Data were acquired in SIM 
mode and alternating SIM/scan mode. In SIM the fragment ion at m/z (M-57) was 
recorded for the 12C and mono 13C species in a specific retention time window: for 
scan acquisition mass spectra were acquired in the range from 40 m/z to 680 m/z. 
Data were acquired and elaborated using the MSD ChemStation software (version 
E.01.01.335, Agilent Technologies). The peaks for malate and fumarate from GC-MS 
signals were integrated, and atom percent excess (13C) values were calculated by 
comparison with control samples and unlabeled standard solutions. It was not 
possible to measure the percent enrichment in oxaloacetate because of the low 
concentration as well as the instability of this substance. 
Sample preparation and 2D Electrophoresis 
For 2DE, cocultured DU145 and CAFs from eight independent experiments, 
separated after 6 hours by MACS column technology, were harvested by 
centrifugation at room temperature. CAFs and DU145 pellets were washed twice in 
PBS and resuspended in 50 mM Tris-HCl pH 7.0, 1% NP-40, 150 mM NaCl, 2 mM 
ethylene glycol bis(2-aminoethyl ether)tetraacetic acid, 100 mM NaF] containing a 
cocktail of protease inhibitors. After sonicated briefly, protein extracts were clarified 
by centrifugation at 14,000 xg for 10 minutes. Proteins were then precipitated 
following the chloroform/methanol protocol previously described [626] and the 
pellet was resuspended in 8 M urea, 4% 3-[(3-cholamidopropyl)dimethylammonio] 
propanesulfonic acid (CHAPS), and 20 mM dithiothreitol (DTT). The protein content 
was determined by using the 2D Quant kit. For each cell lysate sample, four 2DE 
replicate gels were made for each sample, in order to assess biological and 
analytical variation. The first dimension (isoelectric focusing, IEF) was carried out 
on ReadyStrip™ IPG strips, pH 3-10 NL (Bio-Rad) and achieved using the Ettan™ 
IPGphor™ system. IPG-strips were rehydrated with 350 µL of lysis buffer and 2% 
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v/v carrier ampholyte, for 12 hours at room temperature. Sample load, 800 µg per 
strip, was successively performed by cup loading in the IPGphor Cup Loading Strip 
Holders, with the sample cup system at the anodic side of IPG strips. IEF was then 
achieved at 20°C according to the following voltage steps: 30 V for 30 minutes, 200 
V for 2 hours, 500 V for 2 hours, from 500 to 3500 V in 30 minutes, 3500 V for 5 
hours, from 3500 to 5000 V in 30 minutes, 5000 V for 4 hours, from 5000 to 8000 
V in 30 minutes, 8000 V until a total of 95 000 V/h was reached. After focusing, 
prior to the second-dimension separation, IPG strips were equilibrated in 
equilibration buffer (6 M urea, 75 mM Tris-HCl pH 8.8, 29.3% glycerol, 2% SDS) 
containing 1% (w/v) DTT for 15 minutes and then in the same equilibration buffer 
containing 2.5% iodoacetamide for a further 15 minutes. 
The second dimension was carried out on 9-16% polyacrylamide linear gradient gels 
(18 cm × 20 cm × 1.5 mm) at 40 mA/gel constant current and 10°C until the dye 
front reached the bottom of the gel. Protein spots were visualized by colloidal 
coomassie blue staining. The stained gels were scanned with the Epson Expression 
1680 Pro image scanner. Gels containing proteins radiolabeled with 14C-labeled 
amino acids (both CAFs and DU145 proteins) were dried on a Slab Gel Dryer 
(Hoefer, model CD 2000). Dried gels and a storage phosphor screen were inserted in 
an exposure cassette. After an appropriate exposure time (2 days for fibroblasts 
2DE gel and 15 days for DU145 2DE gel) the images were acquired on a Cyclone 
Storage Phosphor Scanner (Perkin Elmer). 
Densitometric analysis of radiolabeled protein spots 
Scanned colloidal coomassie blue images and autoradiographic images relative to 
gels containing 14C-radiolabeled proteins were analysed by the ImageMaster 2D 
Platinum software (GE Healthcare, USA). Only 10 protein spots present in all the 
replicates of both fibroblasts and DU145 gels were taken into consideration for 
subsequent analysis. The relative spot volume (V) was calculated as %V of the total 
volume of 10 selected spots in each gel, corresponding to 14C-radiolabeled proteins. 
The normalized %V of the 10 spots on three replicate 2D gels was averaged and the 
standard deviation was calculated. 
In-gel digestion and MALDI-TOF analysis 
24 protein spots, corresponding to radiolabeled proteins transferred from CAFs to 
DU145 tumor cells, were manually excised from the 2DE gel in which were 
separated the proteins isolated from the cocultured DU145 cells. Samples were 
transferred to a 1.5-mL Eppendorf tube, washed, reduced, carbamidomethylated 
and treated with a trypsin solution (Trypsin Proteomics Sequencing Grade) 
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according a modified protocol from Shevchenko et al [628]. Briefly: protein spots 
were manually excised from gels, washed in 50 mM ammonium bicarbonate 
(NH4HCO3)/CH3CN 1/1, de-hydrated in CH3CN and dried. Prior to proteolytic 
digestion, cysteine residues in proteins were reduced in 10 mM DTT for 30 minutes 
at 56°C and then alkylated for 30 minutes in the dark with 55 mM iodoacetamide in 
25 mM NH4HCO3. Gel particles were then washed, de-hydrated and dried. Each 
sample was finally incubated 1 hour at 37°C in 20 µL of 20 µg/ml trypsin solution 
(Trypsin Proteomics Sequencing Grade) in 40 mM NH4HCO3 with 10% CH3CN. An 
additional 30 µL of 40 mM NH4HCO3 with 10% CH3CN were added to each sample 
and incubated over night at 37°C. The reaction was stopped adding a final 
concentration of 0.1% trifluoroacetic acid. The supernatant was collected and the 
gel was further extracted with 0.1% trifluoracetic acid in 50% CH3CN. The extracts 
were combined and then analysed on a MALDI-TOF/TOF mass spectrometer 
Ultraflex III (Bruker Daltonics, Bremen, Germany) by using Flex Control 3.0 as data 
acquisition software. A 0.75 µL volume of the sample was mixed to 0.75 µL of the 
matrix (saturated solution of α-cyano-4-hydroxycinnamic acid in 50% (v/v) CH3CN 
and 0.5% (v/v) TFA) on the anchorchip target plate and allowed to dry. Spectra were 
acquired in reflectron mode over the m/z range 860-4000 for a total of 500 shots. 
The instrumental parameters were chosen by setting the ion source 1 at 25 kV, ion 
source 2 at 21.5 kV, the pulsed ion extraction at 20 ns and the detector gain at 
7.7x. The instrument was externally calibrated prior to analysis using the Bruker 
Peptide Calibration standard kit. All the resulting mass lists were cleaned up from 
eventually present contaminant masses, such as those from matrix, autodigestion 
of trypsin and keratins. Mass fingerprinting searching was carried out in Swiss-Prot 
databases using MASCOT (Matrix Science Ltd., London, U.K., 
http://www.matrixscience.com) software. The taxonomy was restricted to homo 
sapiens, a mass tolerance of 50 ppm was allowed, and the number of accepted 
missed cleavage sites was set to one. Alkylation of cysteine by 
carbamidomethylation was assumed as fixed modification. The experimental mass 
values were monoisotopic. No restrictions on protein molecular weight and pI were 
applied. The criteria used to accept identifications included the extent of sequence 
coverage, number of matched peptides and probabilistic score sorted by the 
software. 
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Capillary-LC-µESI-MS/MS 
Each peptide mixture was submitted to capillary-LC-µESI-MS/MS analysis on an 
Ultimate 3000 HPLC (Dionex, San Donato Milanese, Milano, Italy) coupled to a LTQ 
Orbitrap mass spectrometer (Thermo Fisher, Bremen, Germany). 
Peptides were concentrated on a precolumn cartridge PepMap100 C18 (300 µm i.d. 
× 5 mm, 5 µm, 100Å, LC Packings Dionex) and then eluted on a homemade 
capillary column packed with Aeris Peptide XB-C18 phase (180 µm i.d. × 15 cm, 3.6 
µm, 100Å, l/min. The loading mobile (Phenomenex, Torrance, CA, USA) at 1 phases 
were: 0.1% TFA in H2O (phase A) and 0.1% TFA in CH3CN (phase B). The elution 
mobile phases composition was: H2O 0.1% formic acid/CH3CN 97/3 (phase A) and 
CH3CN 0.1% formic acid/ H2O 97/3 (phase B). The elution program was: 0 minute, 
4% B; 10 minutes, 40% B; 30 minutes, 65% B; 35 minutes, 65% B; 36 minutes, 
90% B; 40 minutes, 90% B; 41 minutes, 4%B; 60 minutes, 4% B. Mass spectra 
were acquired in positive ion mode, setting the spray voltage at 2 kV, the capillary 
voltage and temperature respectively at 45 V and 200°C, and the tube lens at 130 
V. Data were acquired in data-dependent mode with dynamic exclusion enabled 
(repeat count 2, repeat duration 15 seconds, exclusion duration 30 seconds) survey 
MS scans were recorded in the Orbitrap analyzer in the mass range 300-2000 m/z 
at a 15,000 nominal resolution at m/z = 400; then up to three most intense ions in 
each full MS scan were fragmented (isolation width 3 m/z, normalized collision 
energy 30) and analyzed in the IT analyzer. Monocharged ions did not trigger 
MS/MS experiments. The acquired data were searched with Mascot 2.4 search 
engine (Matrix Science Ltd., London, UK) against the SwissProt database. The 
taxonomy was restricted to homo sapiens. The experimental mass values were 
monoisotopic. Searches were performed allowing: (i) up to one missed cleavage 
sites, (ii) 10 ppm of tolerance for the monoisotopic precursor ion and 0.8 mass units 
for monoisotopic fragment ions, (iii) carbamidomethylation of cysteine as fixed 
modification and oxidation of methionine as variable modification. The criteria used 
to accept identifications included the extent of sequence coverage, number of 
matched peptides and probabilistic score sorted by the software. 
Cluster Analysis 
The identified proteins were subjected to functional pathway analysis using DAVID 
database (http://david.abcc.ncifcrf.gov/home.jsp) for better understanding their 
biological context and hypothesize in which physiological processes they may be 
involved. UniProt accession numbers of the radiolabeled proteins transferred from 
CAFs to DU145 tumor cells identified in our study were uploaded and mapped 
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against the homo sapiens data set to extract and summarize functional annotation 
associated with individual or group of genes/proteins and to identify gene ontology 
terms, molecular function, biological process and important pathways for the 
dataset. 
Small interfering RNA (siRNA) Transfection 
siRNA transfection was performed with Lipofectamine and Opti-MEM to knock-
down CA IX gene expression. CA IX siRNA is a pool of three target-specific 19-25 nt 
siRNAs; a scrambled siRNA was used as control. The cells were used for the 
experiments the day after the transfection. 
Xenograft experiments 
In vivo experiments were performed co-injecting PC3 and fibroblasts knocked down 
for CA IX gene or non-silenced fibroblasts in 6 to 8 week old male severe combined 
immunodeficient (SCID)-bg/bg mice (Charles River Laboratories International). Six 
animals were used per group, which were daily monitored. The tumor size was 
measured every two or three days by a caliper and the tumor volumes were 
determined by measuring the length (L) and the width (W) of the tumor and 
calculating the volume (V=LW2/2). Animals experiments were conducted in 
accordance with national guidelines and approved by the ethical committee of 
Animal Welfare Office of Italian Work Ministry and conform to the legal mandates 
and Italian guidelines for the care and maintenance of laboratory animals. 
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THE EFFECT OF CA IX CATALYSIS PRODUCTS 
WITHIN TUMOR MICROENVIRONMENT 
AIM OF THE STUDY 
The microenvironment of solid tumors is a very complex tissue composed by both 
cellular and non-cellular components. The major cellular elements include 
fibroblasts, endothelial and immune cells, which exhibit an altered phenotype 
induced by cancer cells able to form a permissive and supportive environment for 
tumor progression [629-631]. In fact, these cells produce a range of molecules 
representing the non-cellular components that modify tumor stroma, i.e. ECM 
proteins, proteases, cytokines and growth factors. In particular, many ways in 
which activated fibroblasts of tumor stroma, known as CAFs [82], support tumor 
progression has been described: by secreting growth factors (HGF, EGF, b-FGF) and 
cytokines (SDF-1 and IL-6) leading to the infiltration of immune cells, which, in 
turns promote de novo angiogenesis helping metastatic spread [150]; by remodeling 
ECM and thus influencing proliferation, survival and migration of cancer cells 
[127]; by producing and secreting lactate that is then metabolized by oxygenated 
tumor cells [632]. 
In addition to this unusual composition and behavior of tumor stroma, other 
characteristics that distinguish the tumor microenvironment from the 
corresponding normal tissue are: high interstitial fluid pressure, low O2 tension and 
low pHe. These alterations are due to a perturbation of the balance between pro- 
and anti-angiogenic factors (process known as “angiogenic switch”), which leads to 
the formation of disorganized vasculature with structural and functional 
abnormalities [633], and thus to a reduced perfusion [212]. Other important factors 
responsible for tumor hypoxia and acidity are the high metabolic rate of tumor 
cells, which leads to a massive production of acidic metabolites [254, 259, 260, 275, 
320, 339], and the increased diffusion distances between microvessels and tumor 
cells as result of tumor mass expansion [211]. The hypoxic environment contributes 
to the metabolic shift of cancer cells metabolism towards glycolysis, with the 
additional release of lactic acid in the extracellular milieu [326]. The high protons 
concentration, instead, poses a stress on the cells in that the extracellular 
acidification can ultimately lead to a decrease in pHi. In this condition the control of 
pHi, necessary for cells survival [263], is mediated by different types of pHi 
regulating proteins such as: NHE1, AEs, NBCs, MCTs and CAs [336]. 
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The mammalian CA family contains 16 different isoforms, 13 of which are 
enzymatically active. Their main function is the catalysis of the reversible hydration 
of carbon dioxide to bicarbonate and protons (CO2 + H2O ↔ HCO3- + H+). Among 
them, CA IX is a membrane-bound isoform with the catalytic domain located 
extracellularly and thus is one of the most important proteins involved in tumor 
extracellular acidification. CA IX is overexpressed in hypoxic conditions (a very 
common characteristic in fast growing solid tumors) under tight regulation by HIF-1 
and is associated with cancer progression and poor prognosis [634, 635]. 
The aim of our study was to investigate proliferation and migration of cancer cells in 
the tumor microenvironment context, in particular by analyzing the effect of 
stromal CA IX catalysis products in the modulation of these phenotypes. Our 
experimental model is based on prostatic tumor cells (DU145 and PC3) and 
prostatic primary fibroblasts (HPFs) that, following activation by cancer cells, 
acquire the typical CAFs phenotype [121]. 
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RESULTS 
Cancer cells proliferation within tumor microenvironment 
First, we found that tumor cells kept in hypoxia acidify the extracellular medium 
more than normoxic cells (Figure 1A-C) and that, in coculture, the protons release 
in the extracellular medium is greater than the sum of single culture cell proton 
release (Figure 1B-D). This suggests that the interplay between cancer and stromal 
cells affects important changes in normal and/or in tumor cells metabolism leading 
to an “extra” acidification of the medium. 
In order to evaluate the ability of CAFs to contribute to tumor growth at 
physiological (7.4) as well as acidic (6.8) or basic (8.0) pH, DU145 and PC3 were 
plated and grown for 40 hours in single or in coculture with CAFs at various pHe, 
using CFDA-SE cytofluorymetric assay to measure cell proliferation rate of a given 
 
Figure 1. Effect of hypoxia and coculture on pHe. Tumor and stromal cells were plated in single 
culture (2x105 for each cell type) and in coculture (105 DU145 or PC3 and 105 fibroblasts) at 37°C in 
unbuffered DME medium containing 1 mM bicarbonate in CO2 free atmosphere either at 1% O2 or 20% O2. 
Results show protons concentration values measured in DU145 single and coculture (A-B) and in PC3 
single and coculture (C-D) after 24 hours calculated as a means ± SD from five independent experiments 
(*, p < 0.1; **, p < 0.05; ****, p < 0.005). 
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population in coculture conditions (see Methods). We found that single culture cell 
proliferation rate of both DU145 and PC3 was significantly decreased at acidic pHe 
(Figure 2A-B), without notable presence of cell death in the pHe range considered 
(Table I). In the presence of CAFs, tumor cells proliferation increases at every pHe 
value compared to the corresponding single culture (Figure 2A-B). However, in 
coculture, CAFs attenuate the growth inhibition observed in single culture at pH 
7.4 compared to pH 8.0, but the negative effect of the lowest pH 6.8 is only partially 
offset. 
In addition, the CAFs proliferation rate is significantly greater compared to HPFs 
one (Figure 2C), although the difference is less extensive respect to the reciprocal 
effect of fibroblasts on cancer cells (Figure 2A-B), suggesting that the interplay 
between cancer cells and fibroblasts is mainly devoted to promote tumor cells 
proliferation. 
 
Figure 2. Effect of acidity on tumor cells growth. DU145 (A), PC3 (B) and HPFs (C) were labeled with 
CFDA-SE and then plated in single culture and in coculture. The cells were grown at various pHe in DME 
supplemented with 25 mM hepes and 10 mM bicarbonate at 37°C and 5% CO2. After 40 hours cells were 
detached and analyzed by flow cytometry. The data show the fold increase of proliferation index 
calculated on an average of five experiments (*, p < 0.1; **, p < 0.05; ***, p < 0.01). 
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Table I. Cell death analysis of DU145 and PC3 cells. 
 
 
Tumor cells were were grown in DMEM (pH 8.0) and at various pHe in DME supplemented with 25 mM 
hepes and 10 mM bicarbonate at 37°C and 5% CO2. After 40 hours cell death determination was 
performed by staining cells with Annexin-V-Fluos and flow cytometry analysis. 
 
Figure 3. Effect of acidity on tumor cells growth in hypoxic condition. DU145 (A-B) or PC3 (C-D) 
cells were labeled with CFDA-SE and then plated in single culture and in coculture with fibroblasts in a 
1:2 ratio at 1% O2 and at 20% O2. The cells were grown at various pHe in DME supplemented with 25 mM 
hepes and 10 mM bicarbonate at 37°C and 5% CO2. After 40 hours the cells were detached and analyzed 
by flow cytometry. The data show the proliferation index calculated on an average of six experiments (*, p 
< 0.1; **, p < 0.05; ***, p < 0.01). 
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In order to assess the effect of extracellular acidity in environmental conditions 
more similar to in vivo condition, we compared the growth rate of both PC3 and 
DU145 cells kept at 1% O2 at various pHe. Our results show that hypoxic 
conditions induce a significant increase in tumor cells growth rate compared to 
tumors kept at 20% O2 (Figure 3A-C). Nevertheless, in hypoxia we observed a pH 
dependence cell growth similar to the normoxic conditions, and the same, strong, 
pro-proliferative effect exerted by CAFs on cancer cells proliferation (Figure 3B-D). 
Bicarbonate ion contributes to cancer cells proliferation 
The bicarbonate buffering system is essential to ensure the homeostasis of both pHi 
and pHe. The CO2 reversible hydration is catalyzed by both intra- and extracellular 
CAs. In particular, extracellular CAs are involved in extracellular acidification as 
well as in bicarbonate production. As shown in Figures 2 and 3, a high 
concentration of H+ ions has negative effects on cancer cells proliferation. Thus, we 
investigated the possible involvement of the other product of CO2 hydration, i.e. 
bicarbonate, in tumor cells growth. 
 
Figure 4. Effect of bicarbonate on DU145 tumor cells growth. DU145 were labeled with CFDA-SE 
and then plated in single culture (A), in coculture with fibroblasts in a 1:2 ratio (C) or both (B). The cells 
were grown at various pHe in DME supplemented either with 25 mM hepes and 10 mM bicarbonate at 
37°C and 5% CO2 or in DME supplemented only with 25 mM hepes at 37°C in CO2/bicarbonate free 
environment. After 40 hours cells were detached and analyzed by flow cytometry. The data show the 
proliferation index calculated on an average of four experiments (**, p < 0.05). 
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Therefore we compared the growth rate of tumor cells at 5% CO2 (which 
corresponds to CO2 pressure present in peripheral tissues) in bicarbonate buffer, 
with that kept in CO2-free environment (i.e. at atmospheric CO2 concentration, 
0.032% CO2). Our results show that in single cultures the proliferation index of 
tumor cells (DU145 and PC3) is similar in both conditions, therefore bicarbonate 
does not influence cells growth rate (Figures 4A-5A). 
In cocultures, instead, we found a different behavior in the two tumor cell lines. For 
DU145, we did not observe any difference in growth rate between single culture and 
coculture in CO2-free environment (Figure 4B), while CAFs exerted a powerful pro-
proliferative effect in the presence of 5% CO2 /bicarbonate buffer (Figure 4C). In this 
condition about 90% of the increase in growth rate in the presence of CAFs is due 
to the presence of bicarbonate for each pHe value considered (Table II). For PC3 
cells, instead, the increase in growth rate due to the presence of CAFs occurs partly 
also in CO2-free environment (Figure 5B), bicarbonate being responsible only for 
about 30% of the overall growth rate increase in coculture (Figure 5C and Table II). 
 
Figure 5. Effect of bicarbonate on PC3 tumor cells growth. PC3 were labeled with CFDA-SE and 
then plated in single culture (A), in coculture with fibroblasts in a 1:2 ratio (C) or both (B). The cells were 
grown at various pHe in DME supplemented either with 25 mM hepes and 10 mM bicarbonate at 37°C 
and 5% CO2 or in DME supplemented only with 25 mM hepes at 37°C in CO2/bicarbonate free 
environment. After 40 hours cells were detached and analyzed by flow cytometry. The data show the 
proliferation index calculated on an average of four experiments (**, p < 0.05; ***, p < 0.01). 
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Hence, whereas CAFs contribution to DU145 proliferation is essentially due to 
bicarbonate, PC3 cells largely depend on CAFs for their cell growth, but bicarbonate 
is not the main factor that contributes to this effect. In order to gain information on 
the use of bicarbonate by cancer cells we performed experiments with 14C-
bicarbonate that demonstrate the time-dependent organication of bicarbonate 
(Figure 6). In addition, by using 13C-bicarbonate and GC-MS, we found an increased 
steady state of DU145 intracellular 13C-fumarate and 13C-malate isotopes when they 
are grown in coculture with CAFs compared to single DU145 culture (Table III). This 
evidence indicates an increase in the bicarbonate organication flux in highly 
proliferative conditions. 
Table II. Relative contribution of bicarbonate to DU145 and PC3 growth rate 
increase in coculture. 
 
 
The relative contribution of CO2/bicarbonate was calculated taking into account the relative DU145 and 
PC3 growth rate increase in the presence or in the absence of CO2/bicarbonate in the same conditions. 
 
Figure 6. Bicarbonate organication. DU145 were cultured in DME supplemented with 25 mM hepes, 
10 mM sodium bicarbonate, 20 µM sodium bicarbonate [14C] and 10% FBS at pH 8.0 for 24, 48 and 72 
hours. The data show the CPM (counts per minute) value normalized on protein concentration of each 
sample, calculated on an average of three experiments. 
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The role of stromal cells CA IX in promoting cancer cells 
growth 
DU145 cells growth was significantly fostered in coculture condition exclusively in 
presence of bicarbonate/CO2 buffering system, hence we determined the expression 
level of CA IX, the main responsible for extracellular bicarbonate production, in 
DU145 and in fibroblasts in single culture and after 40 hours of coculture at 1% 
and 20% O2 followed by MACS separation of the two cellular populations. 
Table III. Isotopic analysis by GC-MS. 
 
Isotopic 13C/12C ratio of malate and fumarate extracted from DU145 single culture and from DU145 cells 
separated after being cocultured 40 hours with CAFs. Statistical analysis was performed on the basis of 
three independent experiments. 
 
Figure 7. Analysis of CA IX expression in single culture and in coculture. DU145 and fibroblasts 
were plated in single culture and in coculture in a 1:2 ratio for 40 hours at 20% O2 (A) and 1% O2 (B). 
Similarly, PC3 and fibroblasts were plated in single culture and in coculture in a 1:2 ratio for 40 hours at 
1% O2 (C). After that, the cocultures were detached and separated by MACS Column Technology. The 
samples were lysed in Laemmli electrophoresis buffer and used for Western blot analysis. The 
membranes were treated with anti-CA IX and anti-actin antibodies. Lanes 1 and 2: HPFs and DU145 or 
PC3 in single culture. Lanes 3 and 4: CAFs and DU145 or PC3 after coculture and separation. The graph 
shows spots quantification (D). 
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We observed that CA IX expression in single culture is low both at 1% O2 and 20% 
O2, while it greatly increases only in CAFs after 40 hours of coculture with DU145 
at both O2 tensions (Figure 7A-B). PC3 were less dependent on bicarbonate for their 
growth in coculture (Figure 5C and Table I), accordingly we observed a reduced 
induction of stromal CA IX expression due to PC3 presence (Figure 7C-D) compared 
to that observed after activation of fibroblasts with DU145 (Figure 7A-B). 
In order to assess the role of CAFs CA IX in promoting cancer cells growth, we 
silenced stromal CA IX and measured DU145 growth rate in coculture conditions. 
Our results (Figure 8A-B) show that CAFs knocked down for CA IX are far less able 
to support cancer cells proliferation respect to non-silenced counterpart. In fact, the 
growth rate of DU145 in presence of CAFs knocked down for CA IX decreases both 
at 1% O2 and at 20% O2 and gets close to that of the single culture. 
 
 
Figure 8. Effect of fibroblasts CA IX down-regulation on tumor cells proliferation. DU145 were 
labeled with CFDA-SE and then plated in single culture and in coculture with fibroblasts knocked down 
for CA IX gene or non-silenced, in a 1:2 ratio at 20% O2 (A) and 1% O2 (B). After 40 hours cells were 
detached and analyzed by flow cytometry. The data show the proliferation index calculated on an 
average of four experiments (**, p < 0.05, ***, p < 0.01; ****, p < 0.005). Western blot images show the 
analysis of CA IX expression in non-silenced or knocked down fibroblasts at 20% O2 (A) and 1% O2 (B). 
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Further, to assess the role of stromal CA IX in promoting in vivo tumor growth, we 
co-injected PC3 cells and CAFs (1:5 ratio) in the lateral flanks of SCID-bg/bg mice 
and we observed that fibroblasts knock-down for CA IX are less able to sustain 
tumor mass growth compared to control experiment with non-silenced fibroblasts 
(Figure 9). Linear regression fitting on these data shows that tumor volume growth 
rate is about three times lower in presence of CAFs defective for CA IX expression 
compared to wild type ones. 
Cancer cells migration within tumor microenvironment 
In order to evaluate the role of stromal CA IX in the modulation of cancer cells 
motility, PC3-GFP were plated in single culture or in coculture with CAFs silenced 
or not for CA IX (Figure 10). The fluorescent migrated PC3 were observed by 
fluorescence microscopy. We found that CAFs increase PC3 motility and part of this 
effect is mediated by stromal CA IX expression. In fact, CAFs knocked down for CA 
IX are far less able to promote cancer cells migration with respect to non-silenced 
counterpart. Therefore, in coculture with CA IX-silenced fibroblasts, the number of 
migrating PC3 cells decrease and becomes similar to that of single culture (Figure 
10). This result reveal a correlation between stromal CA IX and migration of tumor 
cells, thus we analyzed the effect of CA IX catalysis products, protons and 
bicarbonate, in the regulation of tumor cells migratory phenotype. First, we 
investigated the effect of high protons concentration on cancer cells migration. In 
this regard, we evaluated migratory capacity of tumor cells at acidic (6.8) and basic 
pH (8.0). Remarkably, single culture cell migration capability of both PC3 (Figure 
 
Figure 9. Silencing of CA IX in fibroblasts decreases tumor growth rate. Xenograft growth in SCID 
bg/bg mice of wild-type (control) or CA IX-silenced CAFs injected s.c. with PC3 cells (CAFs:PC3 cells ratio 
1:5). CA IX silencing by RNA interference in fibroblasts is shown (Timepoint 14 days: ***, p < 0.01; 
timepoint 16 days: ****, p < 0.005). Linear regression equation of “CAFs + PC3”: y=0.08065 (±0.01035) x–
0.82478 (± 0.14473), R2=0.9676; linear regression equation of “CAFs CA IX sil + PC3”: y=0.023219 
(±0.003469) x–0.249096 (±0.051038), R2=0.9563. 
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11) and DU145 (Figure 12) is greater at basic rather than at acidic pH, without 
notable presence of cell death in the pHe range considered (Table I). In particular, 
real-time monitoring of PC3 migration shows that the number of migrated cells is 
quantitatively higher at basic rather than at acid pH (Figure 11). Similarly, wound 
healing test performed with DU145 cell line shows that, although both pHe value 
lead to the acquisition of the migratory phenotype with an elongated shape, after 18 
hours at pH 8.0 cells repaired the wound, instead, at pH 6.8 this action did not 
occur (Figure 12). 
 
Figure 10. Effect of fibroblasts CA IX down-regulation on PC3 migration. PC3-GFP were plated in 
the upper chamber in serum-free medium, while medium supplemented with 10% FBS was placed in the 
well below. Migration assay was performed in single culture and in coculture with fibroblasts knocked 
down for CA IX gene or non-silenced, in a 1:1 ratio. After 18 hours PC3-GFP migrated through the pores, 
to the other side of the membrane were observed by fluorescence microscopy and counted. The data 
show the number of migrated cells calculated on an average of three independent experiments (****, p < 
0.005). Western blot image show the analysis of CA IX expression in non-silenced or knocked down 
fibroblasts. 
 
 
Figure 11. Effect of acidity on PC3 migration. PC3 were plated in the upper chamber at pH 6.8 and 
pH 8.0 in serum-free DME supplemented either with 25 mM hepes and 10 mM bicarbonate at 37°C and 
5% CO2, while media at the same pHe supplemented with 10% FBS were placed in the well below. PC3 
migration was monitored by xCELLigence Real-Time Cell Analyzer (RTCA) DP instrument. 
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In order to evaluate the ability of CAFs to support PC3 motility at acidic as well as 
at physiological (7.4) or basic pH, PC3-GFP were plated in single culture and in 
coculture with CAFs. We found that CAFs enhance PC3 migration rate compared to 
the corresponding single cultures (Figure 13). However, the CAFs-mediated increase 
of PC3 migratory capacity at pH 7.4 and pH 8.0 is considerably higher than that 
observed at pH 6.8. Therefore, we observed a pH dependence cell migration both in 
single culture and in coculture. In both conditions, the acidity of the extracellular 
environment represents a disadvantageous element for the migration process. 
Next, we investigated the possible involvement of bicarbonate (i.e. the other product 
of CO2 hydration) in tumor cells migration. For this experiment, we compared PC3 
migration capability at 5% CO2 in bicarbonate buffer, with that of cells kept in CO2-
free environment. Our results show that single culture PC3 motility is similar in 
both conditions (Figure 14). Also the migration rate of PC3 cocultured with CAFs 
increase in the same extent in CO2-free environment and in CO2/bicarbonate 
buffer, suggesting that bicarbonate produced by stromal CA IX is not involved in 
the regulation of cell migration (Figure 14). 
 
Figure 12. Effect of acidity on DU145 migration. Confluent monolayers of DU145 cells were starved 
overnight with DME at pH 6.8 and pH 8.0 supplemented either with 25 mM hepes and 10 mM 
bicarbonate at 37°C and 5% CO2. After that they were wounded and allowed to migrate. The wound was 
photographed at start and after 18 hours. 
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Figure 13. Effect of acidity on PC3 migration in single culture and coculture conditions. PC3-
GFP were plated in the upper chamber at various pHe in serum-free DME supplemented either with 25 
mM hepes and 10 mM bicarbonate at 37°C and 5% CO2; while media at the same pHe supplemented 
with 10% FBS were placed in the well below. Migration assay was performed both in single culture and 
in coculture with fibroblasts in 1:1 ratio. After 18 hours PC3-GFP cells migrated through the pores to the 
other side of the membrane were observed by fluorescence microscopy and counted. The data show the 
number of migrated cells calculated on an average of three independent experiments (**, p < 0.05; ***, p < 
0.01). 
 
Figure 14. Effect of bicarbonate on PC3 migration. PC3-GFP were plated in the upper chamber at 
pH 7.4 in serum-free DME supplemented either with 25 mM hepes and 10 mM bicarbonate at 37°C and 
5% CO2 or in DME supplemented only with 25 mM hepes at 37°C in CO2/bicarbonate free environment; 
while medium at the same pHe supplemented with 10% FBS was placed in the well below. Migration 
assay was performed both in single culture and in coculture with fibroblasts in 1:1 ratio. After 18 hours 
PC3-GFP cells migrated through the pores to the other side of the membrane were observed by 
fluorescence microscopy and counted. The data show the number of migrated cells calculated on an 
average of three independent experiments. 
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DISCUSSION 
Solid tumors are composed of both highly genetically heterogeneous cancer cells 
and by numerous kinds of non transformed cells composing the so called tumor 
microenvironment. The main cellular component of tumor stroma is represented by 
an activated form of fibroblasts called CAFs. CAFs are widely recognized as key 
players in cancer progression [82, 636] mainly by sustaining tumor cells survival, 
proliferation and metastasis. According with these evidences, the emerging idea is 
that the possibility to counteract tumor progression depends on our understanding 
of cancer tissue physiology intended as a whole and not simply focusing on cancer 
cells behavior outside their physiological condition. 
In this study we investigated the functional cooperation established between CAFs 
and tumor cells in the context of the tumor microenvironment, in particular by 
analyzing the effect of pHe acidification and of CA IX-mediated CO2/bicarbonate 
fluxes in an in vitro coculture model of prostatic tumor. Single culture of HPFs 
produced less pHe acidification compared to cancer cells (PC3 or DU145) both at 
1% O2 and 20% O2 (Figures 1A and 1C) according to the common notion that highly 
proliferating cells, intensifying the glycolytic flux, lead to a strong production and 
release of acidic equivalents to control their pHi. Surprisingly, PC3-CAFs coculture 
(Figure 1D), as well as DU145-CAFs one (Figure 1B), showed a synergistic increment 
of acidic equivalents production. 
The proliferation index determined for each population in single and coculture 
system suggests: 1) PC3 or DU145 cells proliferation rate in single culture are 
highly sensitive to environmental pH. Acidic pHe is a stressful condition for tumor 
cells that leads to a notable reduction of proliferation (Figure 2A-B), without 
presence of cell death (Table I); 2) tumor cells, when cocultured with CAFs, show a 
significant increase in cell proliferation rate at every pHe considered. Nevertheless, 
the presence of CAFs is not sufficient to completely overcome the negative effect of 
acidic pHe (Figure 2A-B); 3) the transdifferentiation of HPFs to CAFs, induced by 
their coculture with tumor cells, leads to an increase in fibroblasts proliferation rate 
(Figure 2C), although at a lesser extent compared to that observed for cancer cells 
(Figure 2A-B); 4) hypoxic conditions, commonly found in tumor microenvironment, 
further contribute to enhance tumor cells proliferation rate both in single culture 
and in coculture (Figure 3A-D). In conclusion, coculture gives a proliferative 
advantage mainly to cancer cells, particularly in hypoxia, whereas pHe acidification 
constitutes a negative environmental condition. 
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One of the proteins responsible for pHe acidification in the context of tumor 
microenvironment is CA IX [255, 304], whose catalytic activity leads to extracellular 
production of protons and bicarbonate. Given that low pHe has a negative impact 
on both PC3 and DU145 proliferation, we have investigated the role of the other 
product of CO2 hydration, bicarbonate, in cancer cells proliferation. Summary data 
reported in Table II show that CAFs-mediated DU145 cells proliferation rate 
enhancement relies almost totally on bicarbonate presence in the extracellular 
medium (Figure 4B-C), while only 30% of PC3 cells proliferation increase due to the 
presence of CAFs is warranted by bicarbonate (Figure 5B-C). 
A key question is why bicarbonate does not influence cells proliferation rate in 
single DU145 and PC3 culture (Figures 4A and 5A). We supposed that bicarbonate 
concentration sufficient for sustaining single culture cell proliferation can be 
obtained by atmospheric CO2 or by cell respiration derived CO2. On the contrary, 
when the growth rate of cancer cells is strongly increased, consequently to CAFs-
mediated activation, bicarbonate concentration is the rate limiting ion both for 
DU145 and PC3 growth. Accordingly, in order to fulfill the demand of bicarbonate 
there is an up-regulation of stromal CA IX when CAFs are cocultured with cancer 
cells. Stromal CA IX up-regulation is linked to the extent of bicarbonate 
contribution to cancer cells proliferation. In fact, we observed a greater CA IX 
expression increase when CAFs were cultured with DU145 (Figure 7A-B) rather than 
with PC3 (Figure 7C-D). 
It has been shown that bicarbonate may serve as a shuttle to transport protons 
outside the cell. In this hypothesis, CO2 hydration by extracellular CAs produces 
protons and bicarbonate, and then the latter is transported within the cell by 
bicarbonate transporters contributing to cytoplasm alkalinization [637, 638] and 
reforming CO2. Our results, indeed, show that tumor cells also use bicarbonate as a 
mono carbonic fragment to build biosynthesis intermediates necessary for sustain 
their high proliferation rate (Figure 6 and Table III) and that this process is 
enhanced in tumor cells cocultured with activated fibroblasts compared to cancer 
cells alone as indicated by the increased steady state concentrations of the two 
Krebs cycle intermediates analyzed (Table III). 
The important role of stromal CA IX for sustaining cancer cells growth has been 
confirmed by siRNA mediated CA IX silencing in CAFs that leads to a remarkable 
decrease of DU145 proliferation compared to standard coculture conditions (Figure 
8A-B). The results of in vitro coculture model are also clearly confirmed by in vivo 
experiments in which we show that CAFs impaired in CA IX expression lead to a 
strong reduction of tumor growth (Figure 9). 
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In summary, these data reveal a new effect of reciprocal interplay between CAFs 
and tumor cells in the context of the tumor microenvironment mediated by CA IX 
catalytic activity. In fact, the up-regulation of stromal CA IX induced by cancer cells 
leads both to the acidification of extracellular milieu and to the production of 
bicarbonate. While extracellular acidification is disadvantageous for cell 
proliferation, bicarbonate, through its organication, supplies cancer cells with 
intermediates useful to sustain their high proliferation rate. It is conceivable that in 
solid tumors the extracellular acidification could be maintained within acceptable 
limits by the dynamics of the extracellular fluid, while CA IX activity ensures the 
amount of bicarbonate sufficient for not constitute a limit to cancer cells growth 
rate. 
Recent study showed that CA IX actively contribute also to cell adhesion and 
migration, two important steps of metastatic process, which enables tumor cells to 
escape the primary mass and colonize new body sites where, at least initially, 
nutrients and space are not limiting. Different ways in which CA IX participates in 
cell motility has been described: by competing with E-cadherin for the interaction 
with β-catenin [322]; by leading to disassemble focal adhesion, mainly through 
inactivation of Rho small GTPase [639]; by co-localizing and physically interacting 
at the leading edge with bicarbonate transporters NBCe1 and AE2, i.e. the pH 
regulating cell apparatus of moving cells [357]. 
Our results show that, not only CA IX expressed by cancer cells, but also that up-
regulated in CAFs surface during coculture conditions (Figure 7A-D) promote cancer 
cells motility. In fact, the increase of cancer cell migration rate observed in 
coculture is remarkably reduced in presence of CA IX silenced CAFs (Figure 10). 
Surprisingly, none of the two CA IX catalysis products have beneficial effect on 
tumor cells migration either in single culture or in coculture. On one hand, the 
CO2/bicarbonate fluxes do not interfere with PC3 migration (Figure 14); on the other 
one, the extracellular acidity represents an unfavorable condition (Figures 11-12). 
The negative effect of high protons concentration is not restored in presence of 
CAFs, and PC3 migration rate remain very low at pH 6.8, instead, significantly 
increase at pH 7.4 and pH 8.0 (Figure 13). 
The migration rate determined for tumor cells both in acidic environment and in the 
presence or absence of bicarbonate buffer system suggest: 1) the migrating cells of a 
tumor mass are present at the periphery (invasion front) of the cancer, where the 
acid/alkaline balance is keep by blood vessels, which remove CO2 and lactic acid. 
Conversely, cells of the central tumor region, where acidic waste accumulates, are 
less able to migrate. This evidence was confirmed by Hlubek et al. [640] who found 
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that dedifferentiated human colorectal carcinoma cells accumulate the 
transcriptional activator β-catenin in the nucleus, in contrast to cells of the tumor 
center; 2) the contribution of stromal CA IX to cancer cells migration is not 
mediated by its catalysis products, indicating that this CA IX effect could be due to 
its non-catalytic related function. Besides its role at the cell surface, a very recent 
study place CA IX among the cell-surface signal transducers undergoing nuclear 
translocation [641]. Therefore, stromal CA IX could contribute to tumor cells 
migration by exhibiting a potential intracellular function. Nevertheless, functional 
aspects of CA IX in tumor cells migration and invasion are still unclear, so future 
investigations are required. 
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NEW CONCEPTS ABOUT FIBROBLASTS 
TROPHIC FUNCTION 
AIM OF THE STUDY 
Fibroblasts are mesenchymal cells with many vital functions both during fetal 
development and in adult organisms. Their main actions are the production and the 
continue remodeling of ECM components, which constitute the structural 
framework, i.e. the connective tissues, of most organs. However, they are also 
important producers of trophic factors. In fact, fibroblasts, mainly mouse embryonic 
fibroblasts or MEFs, have been long used as feeder cell layers for the culture and 
the maintenance of mouse and human embryonic stem cells. In this context, their 
role is to provide a complex mixture of nutrients, cytokines and growth factors for 
the long term survival and proliferation of undifferentiated pluripotent stem cells. 
Fibroblasts, in fact, release various essential growth factors, cytokines and ECM 
components, such as TGF-β, activin A, laminin-511, and vitronectin [642]. 
However, not all the secreted molecules are still known and inconsistencies in 
expression and secretion of these factors make it difficult to determine which 
components are indispensable [642, 643]. 
Besides these functions, fibroblasts are also involved in the regulation of epithelial 
differentiation, in inflammation processes as well as play major roles in wound 
healing. In fact, they are associated with many diseases, either because implicated 
in their inception/progression, or because the hyperactivity of these cells can result 
in excessive production and deposition of ECM components (a process known as 
fibrosis), determining adverse effect on tissues [72]. Fibroblasts play an essential 
role in tumor biology representing the major components of tumor associated 
stroma. These activated fibroblasts are known as CAFs [82]. The transition of a 
normal fibroblast into an activated one is mediated by growth factors and cytokines 
secreted by cancer cells. CAFs, in turns, promote neoplastic progression by 
secreting many cytokines [644, 645]; by releasing lactate that is ultimately 
uploaded by tumor cells [632]; by producing extracellular bicarbonate through the 
catalytic activity of their own CA IX [646]; by ECM remodeling; by stimulating 
inflammation, angiogenesis and lymphangiogenesis [151, 152, 647]. 
The aim of our study was to investigate the ancillary function of fibroblasts, in 
particular in the context of the tumor microenvironment. In our experimental model 
we used non transformed cells, HPFs obtained from surgical explantation of 
patients, human dermal fibroblasts (HDFs), NIH-3T3 murine fibroblasts, and 
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malignant cells, including two different human tumor cell lines of prostatic origin 
(DU145 and PC3) and a human melanoma cell line (A375). The acquisition of the 
typical CAFs phenotype was obtained by coculturing primary fibroblasts with tumor 
cells or with their conditioned medium [121]. 
Since the ability of these cells to secrete soluble signaling molecules has been the 
subject of various study, we analyzed whether the interplay between fibroblasts and 
tumor cells could occur through the horizontal transfer of material, in particular of 
cytoplasmic proteins and membrane lipids. 
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RESULTS 
Fibroblasts transfer proteins and lipids to surrounding cells 
In our experimental model, CAFs are able to promote tumor progression by 
increasing cancer cells proliferation. This analysis was performed by using CFDA-
SE cytofluorymetric assay to measure tumor cells proliferation rate both in single 
culture and in coculture conditions (see Methods). Our results show that DU145 
(Figure 15A) and PC3 (Figure 15B), increase their growth rate of 30-40% when 
cocultured with CAFs and of 10-20% when cultured in their conditioned medium, 
indicating that less than 47% of fibroblasts pro-proliferative effect is mediated by 
the release of soluble factors or by other form of paracrine intercellular crosstalk. 
Always in the context of the tumor microenvironment, we observed that fibroblasts 
are able to horizontally transfer materials to tumor cells. Confocal microscopy of 
fibroblasts labeled with CFDA-SE (to follow the transfer of proteins) or with 
CellVue® (to monitoring the passage of lipids) cocultured with DU145 show that 
fibroblasts transfer both fluorescent proteins (Figure 16A) and lipids (Figure 16B) to 
tumor cells in time dependent manner. On the contrary, when DU145, labeled with 
CFDA-SE or CellVue®, were plated with unlabeled fibroblasts, we did not detect any 
of the two effects: either the passage of proteins (Figure 16C) or of lipids (Figure 
16D). 
 
 
Figure 15. CAFs promote cancer cells growth. DU145 (A) and PC3 (B) were labeled with CFDA-SE 
and then plated in single culture (both in starvation medium and in the medium conditioned by CAFs for 
48 hours) and in coculture with fibroblasts in 1:2 ratio in starvation medium. After 40 hours cells were 
detached and analyzed by flow cytometry. The data show the fold increase of proliferation index 
calculated on an average of four independent experiments (**, p < 0.05; ***, p < 0.01). 
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Figure 16. Confocal microscopy analysis of protein and lipid transfer. Fibroblasts were labeled 
with CFDA-SE (A) or with CellVue® (B) and then plated in coculture with unlabeled DU145 tumor cells in 
2:1 ratio on glass coverslips; in turns, DU145 tumor cells were labeled with CFDA-SE (C) or with CellVue® 
(D) and then plated in coculture with unlabeled fibroblasts in 2:1 ratio on glass coverslips. Immediately 
after plating and after 6 hours the cells were fixed in paraformaldehyde and observed by confocal 
fluorescence microscopy. 
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Thus, the different capability of protein transfer between CAFs and cancer cells was 
quantified by a CFDA-SE cytofluorymetric assay in which we measured the 
fluorescence intensity increase of recipient cells after coculturing with labeled donor 
cells (see Methods). Our results show that CAFs of prostatic and dermal origin 
transfer their proteins to tumor prostatic cells (both DU145 and PC3) and to A375, 
respectively (Figure 17A). On the contrary, the passage of proteins from tumor cells 
to fibroblasts is notably less (Figure 17A). Besides CAFs, also healthy human 
fibroblasts derived from the same anatomical sites (HPFs and HDFs) and 
immortalized, but non transformed, NIH-3T3 murine fibroblasts are able to perform 
this action (Figure 17B). In order to maintain fibroblasts in a non-activated state 
these experiments were carried out by using the same stromal cells as recipients. 
Figure 17B shows that all the types of the tested fibroblasts behave as donor as well 
as recipient cells, in fact, they transfer proteins to the unlabeled surrounding 
counterpart. 
Then, we characterized the kinetic aspect of protein transfer, both evaluating the 
dose- (i.e. the ratio between donor and recipient cells) and the time-dependence. We 
observed that the amount of transferred proteins increases when the ratio between 
recipient tumor cells and donor fibroblasts is in favor of the latter (Figure 18A-B), 
and that the passage of proteins exhibit an increasing trend (Table IV). 
 
Figure 17. Flow cytometry analysis of protein transfer. Fibroblasts of prostatic and dermal origin 
were labeled with CFDA-SE and then plated in coculture in 2:1 ratio with unlabeled prostatic cancer cells 
(both DU145 and PC3) and A375, respectively; in turns, cancer cells of prostatic origin (both DU145 and 
PC3) and A375 were labeled with CFDA-SE and then plated in coculture in 2:1 ratio with unlabeled 
fibroblasts of prostatic and dermal origin, respectively (A). HPFs, HDFs and NIH-3T3 were labeled with 
CFDA-SE and then plated in coculture in a 2:1 ratio with their unlabeled counterpart (B). After 40 hours 
(A) or 24 hours (B) cells were detached and analyzed by flow cytometry. The data represent the value of 
fluorescence intensity increase of recipient cells calculated on an average of three independent 
experiments (**, p < 0.05; *****, p < 0.001). 
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The quantitative analysis of the time-course of protein transfer was performed by 
plating fibroblasts, previously labeled with a mixture of 14C amino acids, and 
prostatic cancer cells (DU145 or PC3) in coculture in 2:1 ratio for 6, 16 and 24 
hours. After that, the two populations were separated and the respective 
radioactivity values were measured by liquid scintillation counter (see Methods). 
The measurement of the radioactivity bound to the proteins transferred from CAFs 
to tumor cells shows that after 24 hours each fibroblast has transferred about 4.0 
% of its total protein mass to a DU145 cell and about 9.5% to a PC3 cell (Table IV). 
 
Figure 18. Kinetic analysis of protein transfer from CAFs to tumor cells. Fibroblasts of prostatic 
origin were labeled with CFDA-SE and then plated with DU145 (A) and PC3 (B) both in 2:1 ratio and 1:2 
ratio. After 40 hours cells were detached and analyzed by flow cytometry. The data represent the value 
of fluorescence intensity increase of recipient cells calculated on an average of three independent 
experiments (*, p < 0.1; **, p < 0.05). 
Table IV. Quantitative analysis of time-course of protein transfer from CAFs 
to tumor cells. 
 
The percentage of CAFs protein mass transferred to tumor cells was obtained from the ratio between 
CAFs radioactivity and that of cancer cell measured for single cell after coculture and separation (CAFs + 
DU145: “6 hours” vs “16 hours” **, p < 0.05; “16 hours” vs “24 hours” **, p < 0.05; CAFs + PC3: “6 
hours” vs “16 hours” **, p < 0.01; “16 hours” vs “24 hours” **, p < 0.01). 
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In order to test the relevance of this mechanism in the context of the tumor 
microenvironment, we compared the transfer capability of healthy fibroblasts with 
respect to CAFs, using healthy stromal cells as recipients. For these experiments, 
healthy prostatic and dermal fibroblasts were previously grown with the medium 
conditioned by their respective tumor cells, and thus converted into CAFs. We 
observed that, although the modulation of this phenomenon depends on the type of 
tumor cell used for fibroblasts activation, CAFs both of prostatic (Figure 19A) and 
dermal origin (Figure 19B) transfer a greater amount of proteins compared to their 
non-activated counterparts. In particular, fibroblasts activated by PC3 increase 
their potential for protein transfer of about 2.66 fold, instead those activated by 
DU145 and A375 show an increase of about 1.5 fold (Figure 19A-B). 
Identification of the proteins transferred from CAFs to tumor 
cells 
Our next goal was to identify some of CAFs proteins transferred to tumor cells. The 
approach we have implemented for the comprehensive profiling and identification of 
the transferred proteins involves the preliminary radiolabeling of fibroblasts 
proteins. Stromal cells were cultured for 72 hours in a complete medium 
supplemented with a mixture of 14C L-amino acids in order to induce their 
 
Figure 19. Quantitative analysis of protein transfer mediated by healthy fibroblasts and 
activated ones. Healthy fibroblasts of prostatic origin (HPFs) and those activated (CAFs) with the 
medium conditioned by prostatic tumor cells, both DU145 and PC3, were labeled with CFDA-SE and then 
plated in coculture with unlabeled healthy fibroblasts in a 2:1 ratio in starvation medium (A). Healthy 
fibroblasts of dermal origin (HDFs) and those activated (CAFs) with the medium conditioned by A375, are 
labeled with CFDA-SE and then plated in coculture with unlabeled healthy fibroblasts in a 2:1 ratio in 
starvation medium (B). After 24 hours cells were detached and analyzed by flow cytometry. The data 
represent the fold increase of the value of fluorescence intensity increase of recipient cells calculated on 
an average of four independent experiments (**, p < 0.05; ***, p < 0.01). CM, medium conditioned by 
tumor cells. 
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incorporation into proteins. Therefore, radioactively labeled fibroblasts were plated 
in coculture with DU145. After 6 hours the two populations were separated, lysed 
and subjected to 2DE. The representative gels of their protein profile obtained after 
colloidal coomassie blue staining are displayed on Figures 20A and 20C, instead, 
Figures 20B and 20D show the corresponding images obtained from the 
autoradiographies of the same gels after being dried. Figure 20B displays the overall 
labeling of fibroblasts proteins, while the DU145 autoradiography (Figure 20D) 
shows limited radiolabeled-protein contents that are proteins derived from CAFs. 
The degree of purity of DU145 isolated after coculture (see Methods), in fact, is 
sufficiently high to exclude that the radioactive signal is due to fibroblasts 
contamination. 
 
Figure 20. Proteomic analysis of CAFs and DU145 after coculture and separation. Radioactively 
labeled CAFs were cocultured with DU145, after 6 hours the two populations were separated and 
subjected to 2DE. The figures show the representative gels of their protein profile after colloidal 
coomassie blue staining (A-C), and display the corresponding images obtained from the 
autoradiographies of the same gels after being dried (B-D). 
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The image analysis and the determination of the specific radioactivity of some 
transferred proteins both in DU145 and in CAFs, further enabled to strengthen our 
hypothesis. We carried out the quantitative analysis of 10 protein spots selected 
among the radiolabeled proteins in DU145 by using the ImageMaster 2D Platinum 
software. These 10 spots were selected for their quality, in fact they are well 
separated from the surrounding ones, compact and non-saturated. The analysis 
was done on both the images related to the stained gels and on autoradiographies. 
For each protein spot we determined the relative spot volume (V) calculated as %V 
with respect to the total volume of the 10 selected spots. The normalized %V of each 
spot on replicate 2D gels was averaged and the standard deviation was calculated 
(Table V). The mean values obtained for the “Prot” (calculated on the spots of 
coomassie stained gels) and for the “14C-Prot” (calculated on 14C spots of the 
autoradiographies) were used to calculate the specific relative radioactivity of each 
spot, both in DU145 and in CAFs gels (%V “14C-Prot”/%V “Prot”). Table VI shows 
the results. The specific enrichment calculated for the 10 spots highlights that a 
selective and specific protein transfer from CAFs to DU145 has occurred. 
 
 
Table V. Quantitative analysis of 14C labeled transferred proteins. 
 
The relative spot volume (V) was calculated as %V of the total volume of 10 selected spots in each gel on 
both the images related to the stained gels (%V “Prot”) and to the autoradiographies (%V “14C-Prot”). The 
resulting values were used to calculate the specific relative radioactivity of each spot and thus the 
specific enrichment of the corresponding proteins. 
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We excised from DU145 gels the main 24 radiolabeled proteins and, after tryptic 
digestion, for each one was produced a peptide mass finger print by MALDI-TOF 
mass spectrometry analysis. Some spots were further analyzed by capillary-LC-
µESI-MS/MS. The identification results were summarized in Table VII. 
In order to gain insight into biological significance of the identified proteins, they 
were categorized according to the DAVID bioinformatics tool. Concerning biological 
processes, the identified proteins were distributed into two main categories. The 
major biological process, in which 50% of them are involved, is “generation of 
precursor metabolites and energy”. Another large part (30%), instead, can be 
grouped in the “cellular component movement” class. The remaining five proteins 
are not associated with common biological processes, so we classified them as 
“other” (Figure 21). 
 
 
 
 
Table VI. Specific enrichment of 14C labeled transferred proteins. 
 
The specific radioactivity was obtained taking into account the relative spot volume of each protein 
calculated with respect to the total volume of the 10 selected spots reported in Table V. In turn, the 
specific enrichment of each protein was obtained from the ratio between the values of specific 
radioactivity calculated in the two cell populations. Red: lowered proteins compared to their contents in 
CAFs; Green: specifically enriched proteins compared to their contents in CAFs. 
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Table VII. Protein identification by MALDI-TOF mass spectrometry and 
capillary-LC-µESI-MS/MS analysis. 
 
Mass lists were cleaned up from eventually present contaminant masses, such as those from matrix, 
autodigestion of trypsin and keratins. Mass fingerprinting or MS/MS searching were carried out in Swiss-
Prot databases using MASCOT (Matrix Science Ltd., London, U.K., http://www.matrixscience.com) 
software. The taxonomy was restricted to human and the number of accepted missed cleavage sites was 
set to one. Alkylation of cysteine by carbamidomethylation was assumed as fixed modification. Oxidation 
of methionine was assumed as variable modification. The experimental mass values were monoisotopic. 
Mass lists were cleaned up from eventually present contaminant masses, such as those from matrix, 
autodigestion of trypsin and keratins and a mass tolerance of 50 ppm was allowed for mass 
fingerprinting searches. A peptide tolerance of 10 ppm and a MS/MS tolerance of 0.6 Da were allowed for 
MS/MS searches. No restrictions on protein molecular weight and pI were applied. The criteria used to 
accept identifications included the extent of sequence coverage, number of matched peptides and 
probabilistic score sorted by the software. 
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The role of extracellular membrane vesicles in fibroblasts-
tumor cells communication 
Besides the networks of soluble molecules, it is known that cell-cell communication 
occurs also through membranous structures, called extracellular vesicles, that 
horizontally transfer biologically active mediators, including nucleic acids, receptors 
and enzymes [407-411]. We characterized the extracellular vesicles released by 
CAFs, and investigated their possible involvement as vehicles in protein transfer 
process to tumor cells. In this regard, the medium recovered from the culture 
supernatant of CAFs was centrifuged (see Methods) and two different fractions of 
vesicles were obtained. In particular, we separated vesicles within 10,000 xg pellet 
from that within 100,000 xg pellet, which were then examined for their size and 
content. 
The size of these particles was revealed by Dynamic Light Scattering analysis. We 
found that the fraction within 10,000 xg pellet contains mainly only one population 
of vesicles with a diameter of about 1 µm (Figure 22A-B), on the contrary, the 
prevalent population of vesicles within 100,000 xg pellet has a diameter of about 20 
nm (Figure 22C-D). Since a uniform nomenclature to define extracellular vesicles 
has not yet been adopted in the literature, in this study, fibroblasts-secreted 
vesicles will be classified exclusively in accordance to their size. Thus, for clarity, we 
will refer to vesicles with a diameter of about 1 µm as microvesicles (MVs), and to 
vesicles with a diameter of about 20 nm as exosomes like-vesicles. 
 
 
 
 
Figure 21. Functional clustering of the identified proteins. Cluster analysis was performed by 
using DAVID database. The pie chart shows the resulting functional interpretation. 
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The composition of these distinct subtypes of vesicles was examined by SDS-PAGE. 
Figure 23A shows the representative gel of their protein profile obtained after 
colloidal coomassie blue staining, instead Figure 23B displays the corresponding 
image obtained from the autoradiography of the same gel after being dried. We 
found that both fractions contain radioactive proteins but with a different 
composition, in particular, MVs are rich in proteins with a molecular weight lower 
than 58 kDa, on the contrary, exosomes-like vesicles are rich in proteins with a 
molecular weight greater than about 40 kDa (Figure 23A-B). 
In order to determine which subtype of particles was responsible for the passage of 
the proteins previously identified, we performed the Western blot analysis. 
 
Figure 22. Size characterization of the vesicles released by CAFs. The vesicles secreted by CAFs 
were isolated and their size distributions were obtained using Dynamic Light Scattering device. The 
average hydrodynamic diameter of vesicles within 10,000 xg pellet is 953.3 ± 168.8 nm (A-B), on the 
contrary, the average hydrodynamic diameter of vesicles within 100,000 xg pellet is 20.75 ± 1.252 nm (C-
D). 
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We found that most of the transferred proteins are more abundant in vesicles with 
a diameter of about 1 µm (Figure 23C), suggesting that MVs are one of the 
mediators that allow the passage of these biological molecules from CAFs to tumor 
cells. 
Finally, we investigated the possible biological roles of these proteins once they 
enter into the recipient cells. Considering the pro-proliferative effect mediated by 
CAFs conditioned medium (Figure 15A-B) and since the transferred proteins have a 
structural role as well as are mainly associated with the generation of precursor 
metabolites and energy (Figure 21), we correlated protein transfer with fibroblasts 
trophic function. In this regard, we found that the proliferation index of DU145 
grown with just MVs increases and gets close to that induced by CAFs conditioned 
medium (Figure 24). 
 
Figure 23. SDS-PAGE and Western blot analysis of the two subpopulations of vesicles obtained 
from the culture supernatant of CAFs. The vesicles released by CAFs were lysed in Laemmli 
electrophoresis buffer and the samples were used for SDS-PAGE. The image shows the gel after colloidal 
coomassie blue staining (A), and display the corresponding image obtained from the autoradiography of 
the same gel after being dried (B). The vesicles recovered from the culture supernatant of CAFs were 
lysed in Laemmli electrophoresis buffer and used for Western blot analysis. The membrane were treated 
with anti-enolase, anti-β-tubulin, anti-glyceraldheide-3-phosphate dehydrogenase (GAPDH), anti-piruvate 
kinase M1 (PKM1), anti-piruvate kinase M2 (PKM2), anti-vimentin, anti-superoxide dismutase 2 (SOD-2) 
and anti-actin (C). 
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Figure 24. Effect of MVs on tumor cells growth. DU145 were labeled with CFDA-SE and then grown 
in starvation medium, in starvation medium supplemented with MVs obtained from the culture 
supernatant of CAFs and in CAFs conditioned medium, respectively. After 40 hours cells were detached 
and analyzed by flow cytometry. The data show the proliferation index calculated on an average of four 
independent experiments (****, p < 0.005; *, p < 0.1). 
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DISCUSSION 
Fibroblasts in mammals comprise a class of highly heterogeneous cell types; in fact 
those isolated from different anatomical sites display distinct and characteristic 
gene-expression patterns, which make these cells poorly defined in molecular terms 
[72]. Despite these different transcriptional patterns, fibroblasts acquire a fine 
functional specialization, for all of them based on the secretion of growth factors 
and ECM components, as well as on the regulation of epithelial differentiation and 
of inflammation [70, 71, 74]. In this study, we add another function shared by 
human fibroblasts derived from different anatomical sites and by fibroblasts of 
murine origin. In particular, we found that healthy human fibroblasts of prostatic 
and dermal origin and non-transformed NIH-3T3 mouse fibroblasts are able to 
transfer cytoplasmic proteins to neighbouring cells (Figure 17B). 
Fibroblasts maintain this property also in pathological conditions, in particular in 
the context of the tumor microenvironment. Our results indicate that CAFs are able 
to horizontally transfer their proteins (Figures 16A and 17A) and lipids (Figure 16B) 
in time-dependent manner to their respective tumor cells. Intriguingly, the passage 
of material from tumor cells to fibroblasts is far less extensive or undetectable. In 
fact, although DU145 transfer proteins to CAFs in a very small extent detectable by 
flow cytometry (Figure 17A), but not by confocal microscopy (Figure 16C), PC3 and 
A375 are not able to perform this type of effect (Figure 17A). Besides protein 
transfer, also the passage of lipids from DU145 to CAFs is very low and not visible 
by confocal microscopy (Figure 16D). These evidences suggest that protein and lipid 
transfer represents an ancillary function of fibroblasts, that they execute both in 
physiological and in pathological conditions, and that, within our tumor 
microenvironment model, it is mainly unidirectional. 
The monitoring of the kinetic aspect showed that the amount of transferred 
material boosts by increasing the ratio between donors and recipients (Figure 18A-
B), and that this passage is time-dependent (Table IV). We quantified that tumor 
cells accumulate the proteins transferred from CAFs so quickly that after just 24 
hours about 4.0% and 9.5% of CAFs total protein mass is transferred to DU145 and 
PC3, respectively (Table IV). Notably, due to the higher mass of fibroblasts with 
respect to that of cancer cells, in real terms the proteins received by cancer cells 
represent a significant fraction of their own overall protein content. 
It is known that activated fibroblasts of the tumor stroma are morphologically and 
functionally different from the quiescent ones, and produce proteases, growth 
factors, cytokines and enzymes [149]. The finding that CAFs, originated from 
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healthy prostatic and dermal fibroblasts, transfer a greater amount of proteins to 
neighbouring cells compared to their healthy counterparts (Figure 19A-B), suggests 
that this differential effect could represent another hallmark of CAFs phenotype. All 
the lines of tumor cells analyzed are able to increase fibroblasts potential for 
horizontal protein transfer, but the modulation of this activation depends on the 
type of tumor cell. In fact, despite DU145 and PC3 cell lines are both models of 
prostate cancer, they regulate this phenomenon in different ways. In particular, 
while fibroblasts activated by DU145 increase their transfer ability of 1.54 fold, the 
amount of proteins transferred from PC3-activated fibroblasts is clearly much 
higher (the transfer increase is about 2.66 fold) (Figure 19A). The A375-mediated 
modulation of fibroblasts potential transfer, instead, is similar to that of DU145 
(Figure 19B). Since the functional conversion of fibroblasts was performed with 
tumor cells conditioned medium, our hypothesis is that the different form of 
regulation could be due to a diverse tumor cells secretion profile both in qualitative 
and quantitative terms. The different degree of modulation mediated by prostatic 
cancer cells conditioned medium is consistent with data showed in Table IV, where 
CAFs transferred a greater amount of their total protein mass when cocultured with 
PC3 rather than DU145. 
The 2DE analysis of radioactively labeled CAFs and DU145 separated after being 
cocultured (Figure 20A-D), allowed us to identified the transferred proteins (Table 
VII) and to discover that this phenomenon is highly specific (Tables V-VI). CAFs 
proteins transferred to DU145 are involved in the generation of precursor 
metabolites and energy, or are structural proteins associated with cellular 
movement (Figure 21). The quantitative analysis of 10 protein spots selected among 
the transferred proteins shows that thioredoxin, galectin-1, SOD-2 (mitochondrial 
isoform) and malate dehydrogenase (cytoplasmic isoform) were specifically enriched, 
while phosphoglycerate mutase 1 and calreticulin were lowered compared to their 
relative content in CAFs, suggesting that protein transfer is a selective and not 
random event (Tables V-VI). 
Further, we reveal that CAFs-secreted MVs play a key role as vehicles in this 
particular form of communication. CAFs of prostatic origin are able to produce two 
subtypes of vesicles: the larger ones were prepared from the whole culture 
supernatant by centrifugation at 10,000 xg, have an average diameter of 953.3 ± 
168.8 nm (Figure 22A-B), and are rich in proteins with a molecular weight lower 
than 58 kDa (Figure 23A-B). The smaller ones, obtained by centrifugation at 
100,000 xg, include a population less homogeneous, where the prevailing fraction 
has a diameter of 20 ± 1.252 nm (Figure 22C-D). Surprisingly, these vesicles are 
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richer in proteins with a molecular weight greater than about 40 kDa (Figure 23A-
B), which, given the small size of these vesicles, might correspond mainly to integral 
membrane proteins. 
Our results show that, between the two subtypes of particles, MVs represent a 
means for the paracrine communication between fibroblasts and tumor cells. They, 
in fact, contain many proteins previously identified, including SOD-2 (mitochondrial 
isoform), GAPDH, α-enolase, tubulin, vimentin, M2 splice isoform of pyruvate 
kinase, and not the M1 isoform which, on the contrary, is more expressed in 
exosome-like vesicles, but is not present among the transferred proteins, thus 
strengthening our hypothesis (Figure 23C and Table VII). Further evidence of MVs 
participation in protein transport from CAFs to DU145 comes from vimentin. In 
particular, we found that vimentin profile in DU145 autoradiography (Figure 20D) is 
similar to that observed in MVs by Western blot analysis (Figure 23C). The various 
spots and bands displayed in both images may correspond to different glycosylated 
or phosphorylated forms of vimentin (Figures 20D and 23C). 
Since MVs shed directly from the plasma membrane, we hypothesized that the 
selective enrichment of some proteins compared to other depends on their uneven 
spatial distribution within cytoplasm. Therefore, the specific selection of certain 
proteins may be due to their prevalent localization close to the plasma membrane 
regions where vesicles bud. The inclusion of mitochondrial proteins inside the 
vesicles (such as SOD-2, malate dehydrogenase and ATP synthase β subunit), 
instead, may occur during their mitochondrial-targeting signal peptide-mediated 
transport. 
The functional role of the passage of these proteins has been confirmed by cell 
proliferation experiments (Figure 24). We found that DU145 increase their growth 
rate of about 8% when cultured in starvation medium supplemented only with MVs, 
suggesting that, besides to soluble factors-mediated cellular crosstalk, also 
membranous vesicles have a part in the pro-proliferative effect observed in tumor 
cells-CAFs coculture (Figure 15A-B). It is noteworthy that this effect could be lower 
compared to what could be achieved in the presence of a continuous production of 
vesicles by fibroblasts in coculture condition (Figure 15A-B). 
In addition, recently Angelucci et al. showed that vimentin protein levels was clearly 
induced in the low-invasive MCF7 cell line cocultured with CAFs, and thus the 
epithelial mesenchymal transition is activated [648]. According to the observation 
that cells by capturing protein cargo contained within these vesicles can extend 
their transcriptome, it is possible that, besides the up-regulated gene-expression, 
fibroblasts-secreted MVs transfer vimentin to tumor cells by sustaining the increase 
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of its protein levels. Indeed, in DU145 autoradiography 5 of the 24 spots analyzed 
were identified as vimentin, which therefore is strongly represented (Figure 20D and 
Table VII). 
In summary, these data reveal a novel role of fibroblasts in the context of the tumor 
microenvironment, which could represent a general property related to the trophic 
function of connective tissue. In fact, in the simplest hypothesis, fibroblasts support 
the survival and proliferation of neighbouring cells (which may be not only tumor 
cells, but also healthy cells) by releasing soluble growth factors and, 
simultaneously, transfer them vesicles laden of proteins and lipids. On one hand, 
growth factors stimulate cell growth and proliferation; on the other hand, protein 
and lipid cargo present into vesicles could increase the rate of mass accumulation 
to the lower limit necessary for cell division. 
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